Name	Binding Type	Structure	Ab patient	Clonal lineage	Isolation paper(Pubmed ID)	Neutralizing antibody feature	Light chain type	# of viruses tested	ADCC	Mean panel IC50	SD panel IC50	Alias	LANL comments
0.5Î³	gp120 V3 // V3 glycan (V3g)		KTS376		Yoshimura2010(20504942) 	Mutations coupling nAb resistance with ceniciviroc sensitivity	K	43	Yes	26.7127	10.3021	0.5gamma, 1C10	
10-1074	gp120 V3 // V3 glycan (V3g)	4FQ2(10-1074 Fab);EMD-20100(B41 SOSIP.664 in complex with SF12 and 10-1074);EMD-20101(B41 SOSIP.664 trimer in complex with 2 Fab fragments of SF12 and 1 Fab fragment of 10-1074);5T3X(Natively Glycosylated BG505 SOSIP.664 in Complex with IOMA and 10-1074);5T3Z(Natively Glycosylated BG505 SOSIP.664 in Complex with IOMA and 10-1074);6OKP(SOSIP.664 in complex with SF12 and 10-1074)	Donor 17	PGT121	Mouquet2012a(23115339) 	10-1074 contacts;10-1074 neutralization;10-1074 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Key sites for PGT121-like and 10-1074-like mAbs;V3 Signature Analysis Summary	L	950	Yes	0.72502	61.5781	10.1074	
10-1074GM	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 			26		1.70613	13.0582		
10-1074-IgG3C-	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Bournazos2016(27315478) 			119		1.33043	48.2715		IgG3C hinge variant
10-1074V	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121		hypervariable loop characteristic correlations with bNAb sensitivity;V3 Signature Analysis Summary		201		0.44827	76.4079		
10-1121	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-1130	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-1146	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-1341	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-1369	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-259	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-303	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-410	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-847	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 		L	10					
10-996	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 	10-996 signature predictions;Key sites for PGT121-like and 10-1074-like mAbs;V3 Signature Analysis Summary	L	121		1.64005	44.6236		
10A3	gp120 V3 // V3 glycan (V3g)		uncoded_rabbit		Qin2015(26039641) 			22		14.4323	20.4026		rabbit antibody
10A37	gp120 V3 // V3 glycan (V3g)		uncoded_rabbit		Qin2015(26039641) 			22		6.98787	20.2343		rabbit antibody
10E8	gp41 MPER (membrane proximal external region)	4U6G(10E8 Fab in complex with a hydrocarbon-stapled HIV-1 gp41 MPER peptide);5T6L(10E8 Fab in complex with the MPER epitope scaffold T117v2);5T80(10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidic acid);5T85(10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidylglycerol);5SY8(10E8 Fab light chain mutant1 and T117v2 HIV-1 MPER scaffold);5TFW(10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold);5T29(10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2);5T5B(10E8 FAB LIGHT CHAIN MUTANT5 AND T117V2 HIV-1 MPER SCAFFOLD);5IQ7(10E8-S74W Fab in complex with an HIV-1 gp41 peptide);5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);5GHW(10E8 with long epitope bound);4G6F(Fab 10E8 complexed with gp41 peptide)	Donor N152	10E8	Huang2012a(23151583) 	10E8 contacts;10E8 residue prediction;10E8 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations affect neutralization by 10E8;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary	L	727	Yes	0.50693	6.4056		
10E8-0fH/0fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		3.87858	5.20716		
10E8-0fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		1.19809	5.99976		
10E8-10fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		0.9675	5.65735		
10E8-10fH/16fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		0.56558	7.15275		
10E8-10fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		2.37887	6.84055		
10E8-19fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		0.44926	8.98017		
10E8-19fH/16fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		0.39459	7.48086		
10E8-2fH/0fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		7.97449	5.97822		
10E8-2fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		0.94299	6.20129		
10E8-2fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Georgiev2014(24391217) 			21		5.13723	5.59785		
10E8 IgG mutant 1	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Irimia2017(28225819) 			108		0.25918	11.6142		
10E8 IgG mutant 2	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Irimia2017(28225819) 			108		2.70736	9.48824		
10E8 IgG mutant 3	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Irimia2017(28225819) 			108		52.1608	2.81275		
10E8 IgG mutant 4	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Irimia2017(28225819) 			0					
10E8 IgG mutant 5	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Irimia2017(28225819) 			108		34.2351	4.21781		
10E8/N6	gp120 CD4bs;gp41 MPER (membrane proximal external region)		Donor N152,Z258		Khan2018(29976677) 			108		0.049453	8.40368	10E8fv-N6fv	bispecific
10E8/PGDM1400/PRO-140	gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region);non-HIV: host CCR5		Donor 84,Donor N152		Khan2018(29976677) 			105		0.012252	6.91922	10E8Fab-PGDM1400fv-PRO140fv	trispecific
10E8/PGT121/PGDM1400.V1	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		0.52481	21.1939	10E8Fab-PGT121fv-PGDM1400fv.V1	trispecific
10E8/PGT121/PGDM1400.V2	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		1.53708	26.254	10E8Fab-PGT121fv-PGDM1400fv.V2	trispecific
10E8/PGT121/PGDM1400.V3	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		0.20382	20.0096	10E8Fab-PGT121fv-PGDM1400fv.V3	trispecific
10E8/PGT121/PGDM1400.V4	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		1.23307	32.5067	10E8Fab-PGT121fv-PGDM1400fv.V4	trispecific
10E8/PGT121/PGDM1400.V5	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		0.21034	19.1657	10E8Fab-PGT121fv-PGDM1400fv.V5	trispecific
10E8/PGT121/PGDM1400.V6	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		0.63234	24.5142	10E8Fab-PGT121fv-PGDM1400fv.V6	trispecific
10E8/PGT121/PGDM1400.V7	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			28		0.42434	17.4206	10E8Fab-PGT121fv-PGDM1400fv.V7	trispecific
10E8/PGT121/PGDM1400.V8	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			114		0.023348	12.7172	10E8Fab-PGT121fv-PGDM1400fv.V8	trispecific
10E8/PGT121/PGDM1400.V8.4DS	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			9				10E8Fab-PGT121fv-PGDM1400fv.V8.4DS	trispecific
10E8/PGT121/PGDM1400.V8Fc	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			27		0.18638	13.9596	10E8Fab-PGT121fv-PGDM1400fv.V8Fc	trispecific
10E8/PGT121/PGDM1400.V8LL	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor 84,Donor N152		Khan2018(29976677) 			12				10E8Fab-PGT121fv-PGDM1400fv.V8LL	trispecific
10E8v1	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Kwon2016(27053554) 		L	0					
10E8V1.1/P140	gp41 MPER (membrane proximal external region);non-HIV: host CCR5		Donor N152		Huang2016(27315479) 			118		0.0025529	7.94089		bispecific
10E8V2.0/iMab	gp41 MPER (membrane proximal external region);non-HIV: host CD4R		Donor N152		Huang2016(27315479) 			154		0.002227	5.6643	10E08-iMab, 10E8-iMAb, 10E8/iMAb	bispecific
10E8v4	gp41 MPER (membrane proximal external region)	5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);7MFB(10E8v4 Fab - light chain H31F variant);7MF7(Crystal structure of antibody 10E8v4-P100gA Fab);6X58(MPER-Fluc-Ec2 bound to 10E8v4 antibody)	Donor N152	10E8	Kwon2016(27053554) 		L	208	Yes	0.41058	6.11526		
10E8v4-5R-100cF	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Kwon2018(29444432) 			208		0.05102	5.58738	10E8v4-5R+100cF 10E8v4-V5R-100cF 10E8v4-V5F-100cF	
10E8v4-DS	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Kwon2016(27053554) 		L	9					
10E8v5	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Kwon2016(27053554) 		L	0					
10J4	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
10M6	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
12A12	gp120 CD4bs		Patient 12	12A12	Scheid2011(21764753) 	12A12 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary	K	237	No	0.22603	10.1948	12A12 d57	
12A21	gp120 CD4bs	4JPW(12a21 in complex with 93th057 gp120 mutant)	Patient 12	12A12	Scheid2011(21764753) 	12A21 alanine scanning;Mutations allowing binding of germline Abs	K	81		2.705	21.3199	12A21 d57	
12G10	gp120 CD4i		KTS376		Tanaka2017(28938888) 		K	0					
1357	gp120 V2 // V2 glycan(V2g) // V2 apex		donor_uncoded_1		Nyambi1998(9765494) 			22		55.2765	3.29435	1357-D	
1361	gp120 V2 // V2 glycan(V2g) // V2 apex		donor_uncoded_1		Nyambi1998(9765494) 			41		58.917	3.3112		
1393A	gp120 V2 // V2 glycan(V2g) // V2 apex		donor_uncoded_1		Nyambi2000(10888650) 			41		65.0711	2.79537		
13I10	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
15e	gp120 CD4bs		N70		Robinson1990c(1694449) 			111	Yes	84.951	1.95986	15E, 1.5e, 1.5E, N70-1.5e	
16G6	gp120 V3 // V3 glycan (V3g)		KTS376		RamirezValdez2015(25486586) 		L	43	Yes	56.5069	6.15609		
1-79	gp120 V3 // V3 glycan (V3g)		Patient 1		Scheid2009(19287373) 		K	18					
179NC75	gp120 CD4bs	7LLK(Q23.17_DS-SOSIP in complex with 179NC75 Fab)	EB179		Freund2015(26516768) 	179NC75 binding-associated sites	L	120		12.6804	32.0116		
17b	gp120 CD4i CoRbs (Cluster C)	1RZ8(antibody 17b);5A8H(BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5A7X(BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);1YYL(CD4M33, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2I5Y(CD4M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);1YYM(F23, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);4RQS(gp120 core bound to CD4 and 17b Fab);1GC1(gp120 core complexed with CD4 and 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);1G9M(gp120 (HXB2) complexed with CD4 and 17b);2NY1(gp120 (I109C, T257S, S334A, S375W, Q428C) complexed with CD4 and 17b);2NY3(gp120 (K231C, T257S, E267C, S334A, S375W) complexed with CD4 and 17b);2NY4(gp120 (K231C, T257S, E268C, S334A, S375W) complexed with CD4 and 17b);2NY6(gp120 (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);2NY2(gp120 (T123C, T257S, S334A, S375W, G431C) complexed with CD4 and 17b);2NXZ(gp120 (T257S, S334A, S375W) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);2I60([Phe23]M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b)	N70			17b contacts;MPER membrane fusion mutations confer sensitivity;Mutation affects binding to 17b and 412d;Mutation affects neutralization;Mutations at the trimer apex that affect sensitivity	K	295	Yes	72.5734	3.44021	1.7b, 1.7B, sCD4-17b	
19.3H-L3	gp120 V3 discontinuous	4F58(Fab structure of neutralizing antibody 19H.3-L3)	R880F		Murphy2013(23468623) 	Mutations affecting neutralization by 19H.3-L3	L	0					
19b	gp120 V3 // V3 glycan (V3g)		N70		Robinson1990c(1694449) 		K	6	No			1.9B, N70-1.9b, N701.9b	
1B2530	gp120 CD4bs	4YFL(1B2530 in complex with HIV-1 clade AE 93TH057 gp120)	Patient 1		Scheid2011(21764753) 	1B2530 contacts;Signature Analysis Summary	L	226		12.3292	9.01227		
1B5	gp120 V2-CD4bs				Strokappe2012(22438910) 			32		22.1425	4.43342	VHH 1B5	llama antibody
1C2	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		13.908	6.2962	VHH 1C2	llama antibody
1D9	gp120 V3 // V3 glycan (V3g)		KTS376		RamirezValdez2015(25486586) 		K	43	Yes	29.0254	10.7902		
1E1	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		70.1952	2.11803	VHH 1E1	llama antibody
1E2	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		67.1795	2.23987	VHH 1E2	llama antibody
1F10	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		9.64739	7.96383	VHH 1F10	llama antibody
1F7	gp120 CD4bs				Buchacher1994(7520721) 		K	117		36.7319	6.60166	human 1F7	
1H9	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		25.1028	4.19244	VHH 1H9	llama antibody
1NC9	gp120 CD4bs		Patient 1		Scheid2011(21764753) 		L	16		3.95204	24.6021		
2158	gp120 V2 // V2 glycan(V2g) // V2 apex	4OAW(Fab structure of V2 mAb 2158)				Mutations at the trimer apex that affect sensitivity		41		64.242	2.90123		
2191	gp120 V3 // V3 glycan (V3g)				Gorny2002(12186887) 			100		45.4818	5.17719		
2219	gp120 V3 // V3 glycan (V3g)	2B0S(antibody 2219 in complex with three different V3 peptides);2B1A(Fab 2219 in complex with UG1033 peptide);2B1H(Fab 2219 in complex with UG29 peptide)			Gorny2002(12186887) 			105		49.8952	4.25128		
246-D	gp41 cluster I				Xu1991(1714520) 		K	1	Yes			246, 246D, SZ-246.D	
2557	gp120 V3 // V3 glycan (V3g)	3MLV(Fab 2557 in complex with an NOF V3 peptide);3MLR(Fab 2557 in complex with a NY5 V3 peptide);3MLT(Fab 2557 in complex with a UG1033 V3 peptide);3MLU(Fab 2557 in complex with a ZAM18 V3 peptide);3MLS(FAb 2557 in complex with gp120 V3 mimotope)			Gorny2004(14963135) 		L	105		61.1682	3.59128		
2558	gp120 V3 // V3 glycan (V3g)	3UJI(Fab 2558 in complex with MN peptide)			Gorny2004(14963135) 		L	100		56.18	4.18878		
25C4b	gp120 CD4i		KTS376		Tanaka2017(28938888) 		K	61		56.3613	3.97586		
2909	quaternary structure	3PIQ(2909 Fab)			Gorny2005(15795308) 			10					
2D4	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		87.3381	1.38607	VHH 2D4	llama antibody
2E7	gp120 V2-CD4bs				Strokappe2012(22438910) 			26		25.145	2.48845	VHH 2E7	llama antibody
2F5	gp41 MPER (membrane proximal external region)	1TJG(2F5 complexed with gp41 7mer epitope);2F5B(2F5 complexed with gp41 epitope);2PR4(2F5 Fab);3BQU(2F5 Fab-3H6 Fab Complex);3MOD(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide);3MOB(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide);3MOA(2F5 Fab fragment with 17 aa gp41 MPER-derived peptide);3IDI(2F5 Fab fragment with gp41 Peptide ALDKWNQ);3IDM(2F5 Fab fragment with gp41 Peptide analog ELD(Nrg)WAS);3IDJ(2F5 Fab fragment with gp41 Peptide analog ELD(Orn)WAS);3IDN(2F5 Fab fragment with gp41 Peptide analog ELD(Paf)WAS);1TJH(2F5 with a gp41 11mer epitope);1TJI(2F5 with a gp41 17mer epitope);3LEV(2F5 with epitope scaffold ES2);3D0L(2F5 with gp41 FP-MPER Hyb3K construct);3DRQ(2F5 with gp41 FP-MPER Hyb3K construct soaked in PEG/2-propanol);1U8H(2F5 with gp41 Peptide ALDKWAS);3IDG(2F5 with gp41 Peptide ALDKWD);1U92(2F5 with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic));1U91(2F5 with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic));1U8P(2F5 with gp41 Peptide ECDKWCS);1U8O(2F5 with gp41 Peptide ELDKHAS);1U8J(2F5 with gp41 Peptide ELDKWAG);1U8I(2F5 with gp41 Peptide ELDKWAN);2PW2(2F5 with gp41 Peptide ELDKWKSL);2PW1(2F5 with gp41 Peptide ELDKWNSL);1U8Q(2F5 with gp41 Peptide ELEKWAS);3DRO(2F5 with gp41 peptide ELLELDKWASLWN);2P8L(2F5 with gp41 Peptide ELLELDKWASLWN);2P8M(2F5 with gp41 Peptide ELLELDKWASLWN in new crystal form);2P8P(2F5 with gp41 Peptide LELDKWASLW[N-Ac]);3D0V(2F5 with gp41 Peptide LLELDKWASLW);3DRT(2F5 with gp41 scrambledFP-MPER scrHyb3K construct);3EGS(2F5 with gp41 scrambledFP-MPER scrHyb3K construct soaked in ammonium sulfate);2F5A(Fab 2F5)			Buchacher1994(7520721) 	2F5 and 4E10 signature sites;2F5 contacts;2F5 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 2F5 binding;Mutation affects sensitivity to neutralization by 2F5 and 4E10;Mutations at the trimer apex that affect sensitivity;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary	K	1009	Yes	15.8297	8.86409	c2F5, IAM 2F5, IAM2F5, IAM-41-2F5	
2G12	gp120 glycans;gp120 glycosylation sites in C2, C3, C4, and V4	EMD-8981(2G12 bound to HIV-1 Env BG505 DS-SOSIP which was also bound to VRC03);6E5P(2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to VRC03);4RBP(2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomanose);3OAU(2G12 Recognizes Di-Mannose);1OM3(Fab 2G12);1OP3(Fab 2G12 bound to disaccharide mannose);1OP5(Fab 2G12 bound to oligosaccharide mannose);1ZLS(Fab 2G12 + Man4);1ZLU(Fab 2G12 + Man5);1ZLV(Fab 2G12 + Man7);1ZLW(Fab 2G12 + Man8);2OQJ(Fab 2G12 with 21-mer peptide ligand);3OAY(Mimic of the HIV glycan shield);3OB0(Mimic of the HIV glycan shield);3OAZ(Mimic of the HIV glycan shield)			Buchacher1994(7520721) 	2G12 contacts;2G12 signature predictions;Mutation affects 2G12 binding;Mutation affects VRC01, PGT151, and 2G12 binding	K	1047	Yes	50.4996	4.80661	c2G12, G12	
2N5	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
3019	gp120 V3 // V3 glycan (V3g)				Gorny2006(16809292) 		L	21		24.59	7.87061		
3074	gp120 V3 // V3 glycan (V3g)	3MLX(Fab 3074 in complex with an MN V3 peptide);3MLY(Fab 3074 in complex with a UR29 V3 peptide);3MLZ(Fab 3074 in complex with a VI191 V3 peptide)			Gorny2006(16809292) 		L	276		53.226	5.22956	V3-3074	
35O22	gp41-gp41 interface	4TOY(35O22 Fab);6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);5U7M(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22);5U7O(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22);6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv);5V7J(BG505 SOSIP.664 Prefusion Env Trimer with Four Glycans removed in Complex with Neutralizing Antibodies 3H+109L and 35O22);5W6D(BG505-SOSIP.v4.1-GT1-N137A in complex with Fabs 35022 and 9H/109L);6OPA(bovine Fab NC-Cow1 in complex with BG505 SOSIP.664 and human Fabs 35022 and PGT128);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5UTF(DS-SOSIP.6mut BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22);5UTY(DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);5T3S(gp140 trimer MD39-10MUTA in complex with Fabs PGT124 and 35022);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5UM8(trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124)	Donor N152	35O22	Huang2014(25186731) 	35O22 contacts;35O22 mutations affecting neutralization;Mutation affects neutralization by 35O22	L	347		2.91957	51.8138	35022	
3694	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		L	21		26.6133	6.82383		
3791	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 	MPER membrane fusion mutations confer sensitivity	K	21		38.8583	6.98744		
3869	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		L	109		62.4526	3.65919		
3881	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		K	21		56.9594	5.03908		
3904	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		K	21		53.9037	4.7151		
3906	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		L	21		26.3043	7.41849		
3BC176	gp41-gp41 interface	5AWN(3BC176 Fab)	Patient 3		Klein2012(22826297) 	3BC176 and 3BC315 key sites;Signature Analysis Summary;Signature Analysis Summary	L	44		9.41136	12.6386		
3BC315	gp41-gp41 interface	5CCK(3BC315 Fab)	Patient 3		Klein2012(22826297) 	3BC176 and 3BC315 key sites	L	37		31.4951	4.15671		
3BNC117	gp120 CD4bs	4JPV(3BNC117 complexed with gp120);4LSV(3BNC117 complexed with gp120 (C1086));5V8M(BG505 SOSIP.664 trimer in complex with 3BNC117);5V8L(BG505 SOSIP.664 trimer in complex with 3BNC117 and PGT145);7PC2(Env in complex with the IgA bNAb 7-269 and 3BNC117);EMD-13316(Env in complex with the IgA bNAb 7-269 and 3BNC117)	Patient 3	3BNC117	Scheid2011(21764753) 	3BNC117 alanine scanning;3BNC117 contacts;3BNC117 signature predictions;Altered glycosylation affects neutralization by CD4BS bnAbs;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 3BNC117 neutralization;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary;Sites selected during 3BNC117 immunotherapy	K	986	Yes	0.54359	21.3884	3BNC117 dRU3	
3BNC117/10-1074	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17,Patient 3		Bournazos2016(27315478) 			120		0.3867	8.31339		bispecific
3BNC117/10-1074-IgG3C-	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17,Patient 3		Bournazos2016(27315478) 			120		0.14654	8.41105		bispecific; IgG3C hinge variant
3BNC117-IgG3C-	gp120 CD4bs		Patient 3		Bournazos2016(27315478) 			119		0.46648	15.5814		IgG3C hinge variant
3BNC117/PGT135-IgG3C-	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 39,Patient 3		Bournazos2016(27315478) 			150		0.069889	11.0323	3BNC117-PGT135	bispecific; IgG3C hinge variant
3BNC55	gp120 CD4bs	5I9Q(3BNC55 Fab in complex with 426c.TM4deltaV1-3 gp120)	Patient 3	3BNC117	Scheid2011(21764753) 	3BNC55 signature predictions;Signature Analysis Summary	K	121		4.68911	15.4342		
3BNC60	gp120 CD4bs	5FEC(3BNC60 Fab germline precursor in complex with 426c.TM4deltaV1-3 gp120);4GW4(3BNC60 Fab with P61A mutation);3RPI(Fab 3BNC60)	Patient 3	3BNC117	Scheid2011(21764753) 	3BNC60 contacts	K	52		0.23941	10.8391		
3BNC62	gp120 CD4bs		Patient 3	3BNC117	Scheid2011(21764753) 		K	15		0.83201	22.4684	BNC62	
3E3	gp120 CD4bs				McCoy2014a(25522326) 			71		1.6937	13.0207		llama antibody
4022	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		L	21		29.5985	7.00816		
4025	gp120 V3 // V3 glycan (V3g)	3UJJ(Fab 4025 in complex with Con A)			Gorny2009(18952295) 		L	21		38.9018	6.75202		
4121	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		L	21		43.5332	4.23385		
4139	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		L	21		42.8949	5.76014		
4210	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		L	21		27.2654	6.72866		
438-B11	gp120 V3 // V3 glycan (V3g)	6V6W(438-B11 DSS mutant (Cys98A-100aA) in complex with an uncleaved prefusion optimized soluble BG505 trimer and Fab 35O22);6UUM(438-B11 DSS mutant (Cys98A-Cys100aA));6UTK(438-B11 Fab in complex with an uncleaved prefusion optimized soluble BG505 trimer and Fab 35O22);6UUH(Crystal structure of broad and potent HIV-1 neutralizing antibody 438-B11)	CBJC438	438-B11	Kumar2020(32938661) 	438-B11 contacts	K	138		4.05621	47.0693	B11	
438-D5	gp120 V3 // V3 glycan (V3g)	6UUL(Crystal structure of broad and potent HIV-1 neutralizing antibody 438-D5)	CBJC438	438-B11	Kumar2020(32938661) 		K	14		1.12934	22.0589	D5	
438-D6	gp120 V3 // V3 glycan (V3g)		CBJC438		Kumar2020(32938661) 		L	12				D6	
438-F11	gp120 V3 // V3 glycan (V3g)		CBJC438		Kumar2020(32938661) 		L	12				F11	
447-52D	gp120 V3 // V3 glycan (V3g)	3C2A(447-52D in complex with UG1033 peptide);1Q1J(Fab 447-52D in complex with V3 peptide);3GHB(Fab 447-52D in complex with V3 peptide 92RW020);4M1D(Fab 447-52D with V3 cyclic peptide MN)			Buchbinder1992(1466965) 	Mutations at the trimer apex that affect sensitivity	L	346	Yes	52.0444	6.58822	447, 447-52-D, 447/52-DII, 447d, 447-D, 447D, 447D-52	
4487	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		L	21		34.0034	5.27528		
4490	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		L	21		39.1782	5.0526		
4508	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		K	21		34.7707	7.50925		
45-46m2	gp120 CD4bs	4JKP(45-46m2 complexed with gp120)	NIH45	VRC01	Diskin2013(23712429) 	45-46m2 signature predictions		134		0.072729	38.6127	m2, NIH45-46 G54W.HC_S28Y.LC	
45-46m25	gp120 CD4bs		NIH45	VRC01	Diskin2013(23712429) 			134		0.19645	24.9044	m25, NIH45-46 G54W_W47I.HC_S28Y.LC	
45-46m28	gp120 CD4bs		NIH45	VRC01	Diskin2013(23712429) 			134		0.13328	26.0761	m28, NIH45-46 G54W_W47T.HC_S28Y.LC, NIH45-46m28	
45-46m7	gp120 CD4bs		NIH45	VRC01	Diskin2013(23712429) 	45-46m7 signature predictions		134		0.1706	25.289	m7, NIH45-46 G54W_W47V.HC_S28Y.LC	
48d	gp120 CD4i	3JWD(gp120 with gp41-Interactive Region with Fab 48D);3JWO(gp120 with gp41-Interactive Region with Fab 48D);1RZ7(Human anti-HIV-1 GP120-reactive antibody 48d);4DVR(YU2 gp120 core in complex with Fab 48d and NBD-557)				Mutations at the trimer apex that affect sensitivity	K	244	Yes	83.8477	2.28492	48D, 4.8d, 4.8D	
49G2	gp120 CD4bs		KTS376		RamirezValdez2015(25486586) 		L	43	Yes	41.0048	7.41274		
4E10	gp41 MPER (membrane proximal external region)	4XCE(4E10 Fab crystalized in the presence of Phosphatidylcholine; C2 space group);4XCC(4E10 Fab crystalized in the presence of Phosphatidylcholine; I422 space group);4XBP(4E10 Fab crystalized in the presence of Phosphatidylethanolamine);4NHC(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41);4NGH(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety);4XAW(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid);4XCF(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with phosphatidylcholine);4XC3(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate);4XC1(4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate);4XBE(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin);4XBG(4E10 Fab in complex with phosphatidic acid: 2.73 A resolution);4XCN(4E10 Fab in complex with phosphatidic acid; 2.9 A resolution);4XCY(4E10 Fab in complex with phosphatidylglycerol);4ODX(4E10 germline encoded precursor no.7 in complex with epitope scaffold T117);5X08(4E10, mutant Npro, with peptide bound);3H3P(Epitope-scaffold 4E10 Fv complex);1TZG(Fab 4E10 complexed with gp41 13mer epitope);2FX8(Fab 4E10 complexed with gp41 Aib-induced peptide);2FX7(Fab 4E10 complexed with gp41 epitope);2FX9(Fab 4e10 with 4e10 epitope on gp41);5CIN(non-neutralizing version of 4E10 (DeltaLoop) with epitope bound);5CIL(non-neutralizing version of 4E10 (WDWD) with epitope bound);4OB5(Ontogeny of recognition specificity and functionality for 4E10);4M62(Ontogeny of recognition specificity and functionality for 4E10);4LRN(Ontogeny of recognition specificity and functionality for 4E10);4M8Q(Ontogeny of recognition specificity and functionality for 4E10);4WY7(recombinant 4E10 expressed in Escherichia coli with epitope bound);5CIP(Unbound 4E10);4LLV(Unbound form of 4E10 Fv)		4E10	Buchacher1994(7520721) 	2F5 and 4E10 signature sites;4E10 contacts;4E10 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 4E10 binding;Mutation affects neutralization;Mutation affects neutralization by PGZL1, H4K3, or 4E10;Mutation affects sensitivity to neutralization by 2F5 and 4E10;Mutations at the trimer apex that affect sensitivity;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary	K	1042	Yes	3.01773	5.38513		
4E9C	gp120 CD4i		KTS376		Yoshimura2010(20504942) 	Mutations coupling nAb resistance with ceniciviroc sensitivity	K	73	Yes	48.4957	5.54632		Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 4E9C was labeled as 917B11.
4O20	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
561_01_18	gp120 CD4bs	6UDJ(bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074);EMD-20739(bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074)	IDC561	561_01_18	Schommers2020(32004464) 	561_01_18 contacts;561_01_18 escape mutations	K	225		0.087878	10.0157	1-18	
561_01_55	gp120 CD4bs	6UDK(bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074);EMD-20740(bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074)	IDC561	561_01_18	Schommers2020(32004464) 		K	133		0.15568	11.3586	1-55	
561_02_12	gp120 CD4bs		IDC561		Schommers2020(32004464) 		K	218		0.23892	26.0208	2-12	
5D6S	gp120 CD4i		KTS376		RamirezValdez2015(25486586) 		K	0					
5G2	gp120 V3 // V3 glycan (V3g)		KTS376		RamirezValdez2015(25486586) 		K	43		43.9838	7.36317		
697-D	gp120 V2 // V2 glycan(V2g) // V2 apex	4D9L(Fab structure of V2 mAb 697)			Gorny1994(7525987) 	Mutations at the trimer apex that affect sensitivity		45		71.7537	2.35329	697-30D, 697D	
7-107	gp120 glycans		pt7	7-269	Lorin2022(35230385) 		K	24	Yes	13.7129	21.1528		
7-155	gp120 glycans		pt7		Lorin2022(35230385) 		K	24	No	24.5629	12.0493		
7-176	gp120 glycans		pt7		Lorin2022(35230385) 		K	24	No	14.6654	16.8089		
717G2	gp120 V3 // V3 glycan (V3g)		KTS376		RamirezValdez2015(25486586) 		K	43	Yes	38.9477	8.86956		
7-269	gp120 glycans	7PC2(Env in complex with the IgA bNAb 7-269 and 3BNC117);EMD-13316(Env in complex with the IgA bNAb 7-269 and 3BNC117)	pt7	7-269	Lorin2022(35230385) 	7-269 contacts	K	56	Yes	5.6157	37.8576		
7B9	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
7H6	gp41 MPER (membrane proximal external region)		Donor N152	10E8	Huang2012a(23151583) 	Q563R affects binding and neutralization of MPER mAbs	L	26		0.42023	8.13379		
7K3	gp41-gp41 interface		Donor N152	35O22	Huang2014(25186731) 		L	8					
830A	gp120 V2 // V2 glycan(V2g) // V2 apex	4YWG(830A in complex with V1V2)			Nyambi2000(10888650) 			41		74.8356	2.7642		
8ANC131	gp120 CD4bs	4RWY(8ANC131 in complex with HIV-1 clade B YU2 gp120)	Patient 8	8ANC131	Scheid2011(21764753) 	8ANC131 contacts;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 8ANC131 neutralization;Signature Analysis Summary	K	192		4.59984	11.8678		
8ANC134	gp120 CD4bs	4RX4(8ANC134 in complex with HIV-1 clade A Q842.d12 gp120)	Patient 8	8ANC131	Scheid2011(21764753) 	8ANC134 contacts	K	174		8.4335	15.9968		
8ANC195	gp41-gp120 interface	4P9M(8ANC195 Fab);5CJX(8ANC195 Fab in complex with BG505 SOSIP.664 HIV-1 Env trimer);4P9H(8ANC195 Fab in complex with gp120 of 93TH057 HIV-1 and soluble CD4 D1D2);5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);5VJ6(BG505 SOSIP.664 in complex with PG9 and 8ANC195);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);5A8H(cryo-ET subtomogram averaging of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5JSA(gp140 trimer with an engineered 10-residue HR1 turn bound to 8ANC195 and PGT128);5JS9(gp140 trimer with an engineered 8-residue HR1 turn bound to 8ANC195 and PGT128);5A7X(negative stain EM of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195)	Patient 8		Scheid2011(21764753) 	8ANC195 contacts;8ANC195 contacts;8ANC195 residue prediction;8ANC195 signature predictions;Mutation affects 8ANC195 neutralization;Signature Analysis Summary	K	272	No	5.9534	12.3504		
8ANC195-IgG3C-	gp41-gp120 interface		Patient 8		Bournazos2016(27315478) 			116		3.67154	15.0125		IgG3C hinge variant
8ANC195/PGT128-IgG3C-	gp120 V3 // V3 glycan (V3g);gp41-gp120 interface		Donor 36,Patient 8		Bournazos2016(27315478) 			116		0.16412	16.5915		bispecific; IgG3C hinge variant
916B2	gp120 CD4i		KTS376		RamirezValdez2015(25486586) 		L	74	Yes	51.6306	5.05756		Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 916B2 was labeled as 4E9C.
917B11	gp120 CD4i		KTS376		RamirezValdez2015(25486586) 		L	43	Yes	52.6175	6.60239		Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 917B11 was labeled as 916B2.
A12	gp120 CD4bs				Forsman2008(18842738) 			73		30.7894	9.19053	VHH A12	llama antibody
A14	gp120 CD4bs				McCoy2014a(25522326) 			61		1.96465	20.132		llama antibody
A16	gp120 CD4bs		F524		Qiao2016(27387828) 	A16 contacts		79		57.3488	3.53445		
A32	gp120 CD4i C1 (Cluster A)	3TNM(A32 Fab, an ADCC mediating anti-HIV-1 antibody);4YBL(stabilized inner domain of clade A/E HIV-1 gp120 in complex with the ADCC mediating ANTI-HIV-1 antibody A32);4YC2(stabilized inner domain of clade A/E HIV-1 gp120 in complex with the antibody A32)				W69 is important for ADCC		36	Yes			A-32	
Ab1485	gp120 V3 // V3 glycan (V3g)	7KDE(BG505 SOSIP.664 with macaque mAb Ab1485 and human mAb 8ANC195)	CE8J		Wang2020(33084569) 	Ab1485 contacts	L	42		4.39027	63.7904		macaque antibody
ACS202	fusion peptide // near gp41-gp120 interface	EMD-8299(AMC011 SOSIP trimer in complex with autologous antibody ACS202)	D12950		vanGils2016(27841852) 	Mutation affects ACS202 neutralization or binding	K	87		5.41892	33.6177		
AIIMS-P01	gp120 V3 // V3 glycan (V3g)		AIIMS_330		Kumar2019(30429339) 			120		3.64015	27.933		
b12	gp120 CD4bs	1N0X(B12 complexed with mimotope);1HZH(B12 unliganded);5VN8(B41 SOSIP.664 in complex with fragment antigen binding variable domain of b12);3RU8(Fab b12 with epitope scaffold);2NY7(gp120 complexed with Fab b12)	Donor b		Burton1991(1719545) 	b12 contacts;b12 signature predictions;b12 signature sites;Mutation affects neutralization;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary	K	1017	Yes	29.2218	7.10037	1b12, b4/12, Fab b12, Ib12, IgG1 b12, IgG1-b12, IgGB12, MAb IgG1b12	
b13	gp120 CD4bs	3IDX(gp120 core in complex with b13);3IDY(gp120 core in complex with b13)	Donor b		Burton1991(1719545) 	Mutations at the trimer apex that affect sensitivity	K	181		71.9753	3.28219		
B21	gp120 CD4bs				McCoy2014a(25522326) 			61		2.9596	17.6827		
b6	gp120 CD4bs		Donor b		Burton1991(1719545) 	MPER membrane fusion mutations confer sensitivity;Mutation decreases binding to CD4BS mAbs	K	65	Yes			IgG1b6	
B9	gp120 CD4bs				McCoy2014a(25522326) 			61		1.76635	20.2176		
BE10			GX2016EU04		Ju2018(30382080) 		K	14		100	1		
BE7			GX2016EU04		Ju2018(30382080) 		K	14		29.3592	17.219		
BF520.1	gp120 V3 // V3 glycan (V3g)	6MN7(BG505.SOSIP.664 in complex with BF520.1 antigen binding fragment)	BF520	BF520	Simonich2016(27345369) 		K	36		16.2187	7.8476		
BF520.1-A52N(HC)	gp120 V3 // V3 glycan (V3g)		BF520	BF520	Wiehe2018(29861171) 		K	13		20.9761	5.02805		
BF8			GX2016EU04		Ju2018(30382080) 		K	14		31.9421	12.6671		
BG1	gp120 V1-V2	5VVF(BG1 Fab);5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195)	EB354		Freund2017(28100831) 		K	119		16.0657	16.2174	354BG1	
BG18	gp120 V3 // V3 glycan (V3g)	6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA)	EB354	BG18	Freund2017(28100831) 	BG18 contacts;BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	L	170		0.66662	95.1206	354BG18	
BG24	gp120 CD4bs	7UCE(BG24 Fab fragment);7UGQ(BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664);7UGP(BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan);7UGM(BG24-iGL CDR3mat Fab);7UGN(BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);7UGO(BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);7UCF(BG505 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);EMD-26494(Cryo-EM map of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 2);EMD-26495(Cryo-EM map of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 3);EMD-26496(Cryo-EM structure of BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664);EMD-26493(Cryo-EM structure of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 1);EMD-26490(Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 1);EMD-26491(Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 2);EMD-26492(Cryo-EM structure of BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);EMD-26443(DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);7UCG(DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24)	391370	BG24	Barnes2022(35960796) 	BG24 contacts;Mutation abrogates BG24 OR VRC01 neutralization;Mutations associated with immunotherapy with BG24 or VRC01	L	139		0.75835	12.2741		
BG24-CDR2-v1	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	128		0.22486	10.727	BG24-PG20-CDR2-v1	
BG24-CDR2-v2	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	128		0.23641	9.44785	BG24-PG20-CDR2-v2	
BG24-G54W	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	128		0.31771	12.7243		
BG24-Y100DW	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	126		3.0299	17.5689		
BG33	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	15		8.17514	15.7693		
BG38	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	20		1.7106	24.7647		
BG5	gp120 CD4bs		391370	BG24	Barnes2022(35960796) 		L	15		6.22045	30.5647		
BG8	gp120 V3 // V3 glycan (V3g)		EB354	BG18	Freund2017(28100831) 		L	117		1.84643	43.5005	354BG8	
BiIA-DG	gp120 V3 // V3 glycan (V3g);non-HIV: host CD4R		Donor 36		Wu2018(29461979) 			40		0.44461	16.383		An engineered tandem bispecific bnAb composed from PGT128, iMab, and ImmunoAdhesin
BiIA-SG	gp120 V3 // V3 glycan (V3g);non-HIV: host CD4R		Donor 36		Wu2018(29461979) 			88		0.016005	9.66693		An engineered tandem bispecific bnAb composed from PGT128, iMab, and ImmunoAdhesin
Bi-NAb	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17,NIH45		Steinhardt2018(29491415) 			208		0.39295	7.9911	Bi-NAb dVRC01-5X-PGT121	bispecific involving VRC01 and PGT121
Bi-ScFv	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17,NIH45		Steinhardt2018(29491415) 			208		0.14478	11.9134	Bi-ScFv dVRC01-5X-PGT121	bispecific involving VRC01 and PGT121
C8	gp120 CD4bs				Forsman2008(18842738) 			67		52.7405	3.87312	VHH C8	llama antibody
CAP228-16H	gp120 V2 // V2 glycan(V2g) // V2 apex	6FY2(CAP228-16H in complex with a heterologous CAP225 V1V2);6FY1(CAP228-16H in complex with a scaffolded autologous V1V2)	CAP228	CAP228-16H	vanEeden2018(30540944) 	Contacts of IGHV5-51 V2 antibodies	L	12	Yes				
CAP228-19F	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP228	CAP228-16H	vanEeden2018(30540944) 		L	12	Yes				
CAP228-3D	gp120 V2 // V2 glycan(V2g) // V2 apex	6FY3(CAP228-3D bound to a heterologous V2 peptide)	CAP228		vanEeden2018(30540944) 	Contacts of IGHV5-51 V2 antibodies	L	12	Yes				
CAP248-2B	fusion peptide // near gp41-gp120 interface	5MP6(Unliganded Fab from CAP248-2B);5F89(Unliganded Fab from CAP248-2B)	CAP248		Wibmer2017(28076415) 	Mutation affects neutralization by CAP248-2B	L	18		44.1122	10.1748		
CAP256V2LS	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256		Zhang2022(36284200) 			296		0.11433	207.014		
CAP257-RH1	gp120 CD4bs	5T33(CAP257-RH1 in complex with strain RHPA gp120 core with an oligomannose N276 glycan)	CAP257		Wibmer2016(27581986) 	CAP257-RH1 contacts;Mutation affects CAP257-RH1 neutralization	L	196		96.2519	1.70482		
CD4-Ig								246		2.60371	7.5296		
CH01	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CH0219	CH01	Bonsignori2011(21795340) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;L184F escapes V2-targeting bnAbs;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;PG9-like antibodies require N160 for neutralization;PG9-like contacts;V2 Signature Analysis Summary	K	386		11.7901	10.718		
CH02	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CH0219	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	K	143		12.23	16.0314		
CH03	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5ESV(CH03 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from Clade C Superinfecting Strain of Donor CAP256)	CH0219	CH01	Bonsignori2011(21795340) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;Mutation affects PG9-like Ab sensitivity;PG9-like contacts	K	90		9.22651	20.6749		
CH04	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	3TCL(Antibody CH04);5ESZ(CH04 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from the Clade AE Strain A244)	CH0219	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	K	155		18.6072	12.7275		
CH103	gp120 CD4bs	4JAM(antibody CH103);4JAN(CH103 in complex with HIV-1 gp120)	Donor CH505	CH103	Liao2013(23552890) 	Antibody-driven selection in donor CH505;CH103 and CH235 evolution;CH103 contacts;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations at the trimer apex that affect sensitivity;Signature Analysis Summary	L	256		4.15305	11.0261		
CH104	gp120 CD4bs		Donor CH505	CH103	Liao2013(23552890) 		L	7					
CH105	gp120 CD4bs		Donor CH505	CH103	Liao2013(23552890) 		L	7					
CH106	gp120 CD4bs		Donor CH505	CH103	Liao2013(23552890) 		L	13					
CH12	gp41 MPER (membrane proximal external region)		CAP206		Morris2011(21980336) 		L	29		70.5082	2.20639	CAP206-CH12	
CH13	gp120 CD4bs		CH0457	CH13	Moody2015(26355218) 	Mutation decreases binding to CD4BS mAbs		37		29.0118	10.8032		
CH14	gp120 V3 // V3 glycan (V3g)		CH0457		Moody2015(26355218) 			52		48.3679	8.7145		
CH16	gp120 CD4bs		CH0457	CH13	Moody2015(26355218) 			48		43.7543	7.61358		
CH17	gp120 CD4bs		CH0457	CH13	Moody2015(26355218) 			48		43.9701	8.29155		
CH18	gp120 CD4bs		CH0457	CH13	Moody2015(26355218) 			48		46.2777	7.03121		
CH235	gp120 CD4bs	EMD-8083(B41 SOSIP.664 trimer in complex with CH235 Fab);EMD-8082(BG505 SOSIP.664 in complex with CH235 Fab);5F9W(CH235 in complex with HIV-1 clade AE 93TH057 gp120)	Donor CH505	CH235	Gao2014(25065977) 	Antibody-driven selection in donor CH505;CH103 and CH235 evolution	K	207		58.7249	3.31513		
CH235.12	gp120 CD4bs	EMD-8079(B41 SOSIP.664 trimer in complex with CH235.12 Fab);EMD-8078(BG505 SOSIP.664 trimer in complex with CH235.12 Fab);5F96(CH235.12 in complex with HIV-1 clade AE 93TH057 gp120)	Donor CH505	CH235	Bonsignori2016(26949186) 	Antibody-driven selection in donor CH505;Electrostatic interactions with D368;hypervariable loop characteristic correlations with bNAb sensitivity;Signature Analysis Summary	K	213		1.00319	6.97703	CH557	
CH235.9	gp120 CD4bs	EMD-8080(B41 SOSIP.664 trimer in complex with CH235.9 Fab);EMD-8081(BG505 SOSIP.664 trimer in complex with CH235.9 Fab);5F9O(CH235.09 in complex with HIV-1 clade AE 93TH057 gp120)	Donor CH505	CH235	Bonsignori2016(26949186) 	Antibody-driven selection in donor CH505;Electrostatic interactions with D368	K	199		6.24706	6.05784	CH235.09, CH493	
CH235-L47W(HC)	gp120 CD4bs		Donor CH505	CH235	Wiehe2018(29861171) 		K	13		68.2638	3.75302		
CH235-Q23K(HC)	gp120 CD4bs		Donor CH505	CH235	Wiehe2018(29861171) 		K	13		37.0384	5.53909		
CH235-Q46E(HC)	gp120 CD4bs		Donor CH505	CH235	Wiehe2018(29861171) 		K	13		33.8719	5.91156		
CH235-R57S(HC)	gp120 CD4bs		Donor CH505	CH235	Wiehe2018(29861171) 		K	13		80.6445	2.10685		
CH235-T19K(HC)	gp120 CD4bs		Donor CH505	CH235	Wiehe2018(29861171) 		K	16		41.0872	4.97077		
CH235-W55G(HC)	gp120 CD4bs		Donor CH505	CH235	Wiehe2018(29861171) 		K	13		72.9702	2.97905		
CH27	gp120 CD4bs		CH0457	CH27	Moody2015(26355218) 			52		32.1877	9.71576		
CH28	gp120 CD4bs		CH0457	CH27	Moody2015(26355218) 	Mutation decreases binding to CD4BS mAbs		48		10.2164	18.223		
CH44	gp120 CD4bs		CH0457	CH27	Moody2015(26355218) 	Signature Analysis Summary		48		12.6426	13.6918		
CH45	gp120 CD4bs		CH0457	CH13	Moody2015(26355218) 			48		65.2365	3.88002		
CH46	gp120 CD4bs		CH0457	CH13	Moody2015(26355218) 			0					
CH48	gp120 V3 // V3 glycan (V3g)		CH0457		Moody2015(26355218) 			52		42.3533	9.47883		
CH58	gp120 V2 // V2 glycan(V2g) // V2 apex	4HQQ(RV144-elicited antibody CH58);4HPO(RV144-elicited antibody CH58 in complex with V2 peptide)	347759		Liao2013b(23313589) 	Contacts and binding of CH58 and CH59;Contacts of IGHV5-51 V2 antibodies	L	15	Yes	87.0259	1.65044		
CH59	gp120 V2 // V2 glycan(V2g) // V2 apex	4HPY(RV144-elicited antibody CH59 in complex with V2 peptide)	347759		Liao2013b(23313589) 	Contacts and binding of CH58 and CH59	L	9	Yes				
CH98	gp120 CD4bs		CH5329		Bonsignori2014(24614107) 	Mutation decreases binding to CD4BS mAbs	L	42		10.0009	10.7667		
D7	gp120 CD4bs				Forsman2008(18842738) 			63		45.9572	6.12633	VHH D7	
DH270.1	gp120 V3 // V3 glycan (V3g)	5U0U(DH270.1 (unliganded, single-chain Fv))	CH848	DH270	Bonsignori2017(28298420) 	V3 Signature Analysis Summary	L	210		10.6907	17.4537	DH270	
DH270.2	gp120 V3 // V3 glycan (V3g)		CH848	DH270	Bonsignori2017(28298420) 		L	32		1.87215	24.245	DH473	
DH270.3	gp120 V3 // V3 glycan (V3g)	6CBJ(DH270.3 Fab in complex with Man9);5TPL(DH270.3 unliganded)	CH848	DH270	Bonsignori2017(28298420) 		L	27		14.1611	14.7117	DH391	
DH270.4	gp120 V3 // V3 glycan (V3g)		CH848	DH270	Bonsignori2017(28298420) 		L	48		0.73671	31.5641	DH429	
DH270.5	gp120 V3 // V3 glycan (V3g)	5TPP(DH270.5 (unliganded))	CH848	DH270	Bonsignori2017(28298420) 	V3 Signature Analysis Summary	L	210		5.93299	24.2443	DH471	
DH270.6	gp120 V3 // V3 glycan (V3g)	6CBP(DH270.6 bnAb in complex with the Man9-V3 glycopeptide);5TQA(DH270.6 (unliganded))	CH848	DH270	Bonsignori2017(28298420) 	hypervariable loop characteristic correlations with bNAb sensitivity;V3 Signature Analysis Summary	L	215		2.71164	35.2194		
DH270 IA1	gp120 V3 // V3 glycan (V3g)		CH848	DH270	Bonsignori2017(28298420) 		L	27		0.79309	34.2106		
DH270 IA2	gp120 V3 // V3 glycan (V3g)		CH848	DH270	Bonsignori2017(28298420) 		L	32		8.21191	19.2654	DH270 I2	
DH270 IA3	gp120 V3 // V3 glycan (V3g)		CH848	DH270	Bonsignori2017(28298420) 		L	27		19.1294	10.6103		
DH270 IA4	gp120 V3 // V3 glycan (V3g)		CH848	DH270	Bonsignori2017(28298420) 		L	27		62.349	3.85642		
DH511.1	gp41 MPER (membrane proximal external region)	5U3J(DH511.1 Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210	DH511	Williams2017(28783671) 		K	41		0.62322	6.66116		
DH511.10P	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	0					
DH511.11P	gp41 MPER (membrane proximal external region)	5U3M(DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210	DH511	Williams2017(28783671) 		K	210		0.64487	5.30457		
DH511.12P	gp41 MPER (membrane proximal external region)	5U3N(DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210	DH511	Williams2017(28783671) 		K	210		0.5949	5.17193		
DH511.2	gp41 MPER (membrane proximal external region)	5U3K(DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide);5U3L(DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide)	CH0210	DH511	Williams2017(28783671) 	DH511.2 and DH511.2_K3 contacts;Signature Analysis Summary	K	382		1.06803	6.49489		
DH511.2_K3	gp41 MPER (membrane proximal external region)	5U3O(DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210	DH511	Williams2017(28783671) 	DH511.2 and DH511.2_K3 contacts;Signature Analysis Summary	K	302		0.34124	5.79184	DH511.2 K3, DH511 K3	chimeric: heavy chain from DH511.2 + light chain from DH511.8P
DH511.3	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	41		1.28786	6.73283		
DH511.4	gp41 MPER (membrane proximal external region)	5U3P(DH511.4 Fab)	CH0210	DH511	Williams2017(28783671) 		K	41		1.78849	4.40134		
DH511.5	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	41		1.52602	5.60216		
DH511.6	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	41		1.34659	8.10451		
DH511.7P	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	0					
DH511.8P	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	0					
DH511.9P	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	0					
DH511_I1	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH511_I2	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH511_I3	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH511_I4	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH511_I5	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH511_I6	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH511_UCA	gp41 MPER (membrane proximal external region)		CH0210	DH511	Williams2017(28783671) 		K	12					
DH512	gp41 MPER (membrane proximal external region)		CH0210		Haynes2016a() 		K	220		0.84237	7.89035	Ab510049	
DH517	gp41 MPER (membrane proximal external region)		CH0210		Williams2017(28783671) 		L	32		17.394	9.28817	Ab510053	
DH563	gp120 V3 // V3 glycan (V3g)		CH765	VRC41	Alam2017(28298421) 	Mutation affects neutralization of V3 mAbs	K	30		28.4967	3.61814	CH765-DH563	
DH651.1	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.2	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.3	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.4	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.5	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.6	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.7	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	12					
DH651.8	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Bonsignori2018(30552024) 		K	12					
DH651.9	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Bonsignori2018(30552024) 		K	12					
DRVIA1	gp120 CD4bs		DRVI01	DRVIA1-6b	Kong2016(27067056) 		K	8					
DRVIA3	gp120 CD4bs		DRVI01	DRVIA1-6b	Kong2016(27067056) 		K	24		78.3911	3.21425		
DRVIA4	gp120 CD4bs		DRVI01	DRVIA1-6b	Kong2016(27067056) 		K	8					
DRVIA6b	gp120 CD4bs		DRVI01	DRVIA1-6b	Kong2016(27067056) 		K	8					
DRVIA7	gp120 CD4bs	5CD3(Immature DRVIA7);5CD5(Immature DRVIA7 bound to clade A/E HIV-1 gp120 core);EMD-6372(JRFL Env SOSIP.664 in complex with DRVIA7);EMD-6373(JRFL Env SOSIP.664 in complex with hybrid antibody DRVIA7/VRC01)	DRVI01		Kong2016(27067056) 	DRVIA7 contacts	K	85		30.9708	9.14724	A7	
DRVIA7H-VRC01L	gp120 CD4bs		DRVI01,NIH45		Kong2016(27067056) 		K	51		4.07941	9.45761	DRVIA7H+ VRC01L	
F105	gp120 CD4bs	1U6A(Fab F105);3HI1(gp120 (core with V3) complex with F105)			Posner1991(1710248) 	Mutations at the trimer apex that affect sensitivity	K	248	Yes	74.8148	3.14566	F-105	
F2			GX2016EU04		Ju2018(30382080) 		K	14		39.5362	9.9704		
F4			GX2016EU04		Ju2018(30382080) 		K	14		27.6318	16.9226		
F425 B4e8	gp120 V3 // V3 glycan (V3g)	2QSC(Fab F425-B4e8 in complex with a V3-peptide)			Cavacini2003(12646791) 	Mutations at the trimer apex that affect sensitivity		21				B4e8, F425, F425b, F425-B4e8, F425B4e8	
F6	gp120		GX2016EU04		Ju2018(30382080) 		K	37		30.2306	3.85063		
F8			GX2016EU04		Ju2018(30382080) 		K	14		32.9787	15.9841		
gVRC-H1dC38/VRC01L	gp120 CD4bs		C38,NIH45		Zhu2013a(24106303) 		K	153		1.52584	11.0448		chimeric
H6			GX2016EU04		Ju2018(30382080) 		K	14		47.919	6.13045		
HG107	gp120 V2 // V2 glycan(V2g) // V2 apex		200134		Liao2013b(23313589) 		L	2	Yes				
HG120	gp120 V2 // V2 glycan(V2g) // V2 apex		302689		Liao2013b(23313589) 		L	2	Yes				
HGN194	gp120 V3 // V3 glycan (V3g)		VI3265		Corti2010(20098712) 			93		41.2735	8.6293		
HJ16	gp120 CD4bs	4YE4(Neutralizing Antibody HJ16 in Complex with HIV-1 gp120)	VI3208		Corti2010(20098712) 	HJ16 binding requires N276;HJ16 contacts;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary	K	310		18.844	15.5049	HJ16_22	
HK20	gp41 NHR (N-heptad repeat)	2XRA(HK20 Fab in complex with a gp41 mimetic 5-Helix)	VI3081		Corti2010(20098712) 			98	Yes	94.9494	1.2932		
IA-Hu5A8	non-HIV: host CD4R				Wu2018(29461979) 			40		0.08637	7.42203	IA-iMab	iMab variant that includes ImmunoAdhesin
IA-PGT128	gp120 V3 // V3 glycan (V3g)		Donor 36	PGT128				40		0.91676	32.6088		Engineered form of PGT128 that includes ImmunoAdhesin
iMab	non-HIV: host CD4R	3O2D(CD4 in complex with a potent antiviral antibody)						130		0.092014	10.111	5A8, Hu5A8, ibalizumab, TMB-355, TNX-335	iMab is an anti-CD4 receptor antibody (not anti-HIV)
iMab-CAP256	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R		CAP256		Moshoette2019(31703699) 			20		0.0017699	14.8957		bispecific
iMab-N6	gp120 CD4bs;non-HIV: host CD4R		Z258		Moshoette2022(36071449) 			21		0.047116	3.13508		bispecific
IOMA	gp120 CD4bs	6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA);5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074)	R1		Gristick2016(27617431) 	IOMA contacts	L	245		12.8509	10.7645	IOMA.25	
J3	gp120 CD4bs				McCoy2012(22641382) 			104		0.86234	5.5542	L8CJ3, VHH J3	llama antibody
JM2	gp120 CD4bs				Matz2013(23152508) 			20		41.385	5.39358		llama antibody
JM3	gp120-CD4 complex				Matz2013(23152508) 			22		17.5591	5.39603		llama antibody
JM4	gp120 CD4bs;gp120 CD4i	4LAJ(JM4 in complex with YU2 gp120 and CD4-mimetic miniprotein M48U1)			Matz2013(23152508) 			65		15.086	9.38502	JM4sdAb, JM4SdAb	llama antibody
JM4-IgG2b	gp120 CD4bs;gp120 CD4i				Acharya2013(23843638) 			195		0.27111	11.9335		llama antibody
JM4-IgG3	gp120 CD4bs;gp120 CD4i				Acharya2013(23843638) 			30		0.71993	8.96791		llama antibody
JM5	gp120-CD4 complex				Matz2013(23152508) 			21		44.7172	4.30427		llama antibody
KD-247	gp120 V3 // V3 glycan (V3g)	3NTC(KD-247 Fab)			Eda2006a(16699036) 			43	Yes	38.95	7.78897		mouse antibody
LN01	gp41 MPER (membrane proximal external region)	6SNC(LN01 Fab in complex with an HIV-1 gp41 peptide);6SNE(LN01 Fab in complex with an HIV-1 gp41 peptide);6SND(LN01 Fab in complex with an HIV-1 gp41 peptide)	SA003		Pinto2019(31653484) 	LN01 contacts	K	118	Yes	1.36778	7.16531		
M36/PRO-140	gp120 CD4i;non-HIV: host CCR5				Khan2018(29976677) 			107		0.011253	6.26089	m36.4fv-PRO-140fv	bispecific
m66	gp41 MPER (membrane proximal external region)	4NRY(Antibody m66);4NRX(m66 in complex with gp41 MPER peptide)	SC44		Zhu2011(21880764) 	Mutation decreases binding of m66 and m66.6	K	170		95.5721	1.41734		
m66.6	gp41 MPER (membrane proximal external region)	4NRZ(Antibody m66.6)	SC44		Zhu2011(21880764) 	Mutation decreases binding of m66 and m66.6	K	170		60.0523	2.79623	M66.6	
m66 G30(LC)K	gp41 MPER (membrane proximal external region)		SC44		Ofek2014(24335316) 			47		38.1883	3.21715	m66-G30K, m66 G30 LCK, m66G30 LCK, m66G30LCK	
m66 S28(LC)H	gp41 MPER (membrane proximal external region)		SC44		Ofek2014(24335316) 			40		92.8194	1.38582	m66-S28H, m66 S28 LCH, m66S28 LCH, m66S28LCH	
m66 S28(LC)H-G30(LC)K	gp41 MPER (membrane proximal external region)		SC44		Ofek2014(24335316) 			40		33.5914	4.54709	m66-S28H-G30K, m66 S28 LCH-G30 LCK, m66S28 LCH-G30 LCK, m66S28LCH-G30LCK	
m66 S28(LC)H-G30(LC)K-S31(LC)K	gp41 MPER (membrane proximal external region)		SC44		Ofek2014(24335316) 			47		18.3974	4.06931	m66-S28H-G30K-S31K, m66 S28 LCH-G30 LCK-S31 LCK, m66S28 LCH-G30 LCK-S31 LCK, m66S28LCH-G30LCK-S31LCK	
m66 S31(LC)K	gp41 MPER (membrane proximal external region)		SC44		Ofek2014(24335316) 			40		81.7427	1.64876	m66-S31K, m66 S31 LCK, m66S31 LCK, m66S31LCK	
m66 Y100e(HC)W	gp41 MPER (membrane proximal external region)		SC44		Ofek2014(24335316) 			47		50.6663	3.78111	m66 Y100e HCW, m66Y100e HCW, m66Y100eHCW, m66-Y100eW	
MEL-1842	gp120 CD4bs		Cow #1		Heydarchi2022(35584627) 		L	47		0.34016	108.455		The light chain gene of MEL-1842 was not rescued, so it was produced using the MEL-2129 light chain.
MEL-1872	gp120 CD4bs		Cow #1		Heydarchi2022(35584627) 	Mutation affects binding or neutralization of MEL-1872	L	47		0.21885	113.074		The light chain gene of MEL-1872 was not rescued, so it was produced using the MEL-2129 light chain.
MEL-2129	gp120 CD4bs		Cow #1		Heydarchi2022(35584627) 		L	46		2.89666	54.3181		
Minimal BF520.1	gp120 V3 // V3 glycan (V3g)		BF520	BF520	Simonich2019(31097697) 		K	13				Minimal VH Minimal VK	
N49P11	gp120 CD4bs;gp120 CD4i		N49	N49P6	Sajadi2018(29731169) 		L	117		1.19929	5.72401		
N49P18.1	gp120 CD4bs;gp120 CD4i		N49	N49P6	Sajadi2018(29731169) 		L	117		14.146	4.03303		Unpublished N49P18.1 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169)
N49P19	gp120 CD4bs;gp120 CD4i		N49	N49P6	Sajadi2018(29731169) 		L	117		4.97479	10.9474		Unpublished N49P19 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169)
N49P22			N49		Sajadi2018(29731169) 			117		10.0963	11.606		Unpublished N49P22 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169)
N49P23			N49		Sajadi2018(29731169) 			117		0.89302	40.7691		Unpublished N49P23 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169)
N49P6	gp120 CD4bs;gp120 CD4i;quaternary structure	6OZ4(N49P6 with HIV-1 BG505 SOSIP.664 Env trimer ectodomain);6OZ2(N49P6 with HIV-1 strain 93TH057 gp120 core)	N49	N49P6	Sajadi2018(29731169) 	N49P6 contacts	L	117		0.5532	8.55265		Structural analysis from Tolbert2021 (PMID 34281393)
N49P7	gp120 CD4bs;gp120 CD4i	6BCK(N49P7 with HIV-1 strain 93TH057 gp120 core)	N49	N49P6	Sajadi2018(29731169) 	N49P7 contacts	L	293		0.30592	8.43089		
N49P7.1	gp120 CD4bs;gp120 CD4i		N49	N49P6	Sajadi2018(29731169) 		L	117		0.20684	5.99105		
N49P7.2	gp120 CD4bs;gp120 CD4i		N49	N49P6	Sajadi2018(29731169) 		L	117		0.44283	11.4521		Unpublished N49P7.2 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169)
N49P7.v2	gp120 CD4bs		N49	N49P6	Kwon2021(34328065) 		L	208		0.10327	5.71933		
N49P9	gp120 CD4bs		N49	N49P9	Sajadi2018(29731169) 		L	117		0.28921	11.5878		
N49P9.1	gp120 CD4bs	6OZ3(N49P9.1 with HIV-1 strain 93TH057 gp120 core)	N49	N49P9	Sajadi2018(29731169) 		L	117		0.42484	12.5522		Unpublished N49P9.1 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169)
N6	gp120 CD4bs	5TE5(N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core);5TE6(N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core);5TE4(N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core)	Z258		Huang2016a(27851912) 	hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects N6 neutralization;N6 alanine scanning;N6 contacts;Signature Analysis Summary	K	484		0.075376	5.93613		
N60P1.1	gp120 CD4bs	5WB9(N60P23 with 93TH057 gp120 core (N60P23 differs from N60P1.1 by 1 AA))	N60	N60 lineage 1	Sajadi2018(29731169) 		K	73		5.85446	11.1567		Structure 5WB9 is for mAb N60P23 which differs from N60P1.1 by 1 AA
N60P2.1	gp120 CD4bs		N60	N60 lineage 1	Sajadi2018(29731169) 		K	73		9.93875	13.3704		
N60P22	gp120 CD4bs		N60	N60 lineage 2	Sajadi2018(29731169) 		K	73		88.7001	1.78535		
N60P25.1	gp120 CD4bs		N60	N60 lineage 1	Sajadi2018(29731169) 		K	72		3.49384	13.6202		
N60P30	gp120 CD4i cluster A		N60	N60 lineage 3	Sajadi2018(29731169) 		K	0					
N60P31.1	gp120 CD4bs		N60	N60 lineage 1	Sajadi2018(29731169) 		K	73		43.0735	7.3424		
N60P35	gp120 V3 // V3 glycan (V3g)		N60	N60 lineage 7	Sajadi2018(29731169) 		L	0					
N60P36	gp120 CD4i CoRbs (Cluster C)		N60	N60 lineage 4	Sajadi2018(29731169) 		K	0					
N60P37	gp120 V3 // V3 glycan (V3g)		N60	N60 lineage 7	Sajadi2018(29731169) 		L	0					
N60P38	gp120 CD4bs		N60	N60 lineage 2	Sajadi2018(29731169) 		K	0					
N60P39	gp120 CD4i CoRbs (Cluster C)		N60	N60 lineage 5	Sajadi2018(29731169) 		K	0					
N60P39.1	gp120 CD4i CoRbs (Cluster C)		N60	N60 lineage 5	Sajadi2018(29731169) 		K	0					
N60P47	gp120 CD4i CoRbs (Cluster C)		N60	N60 lineage 5	Sajadi2018(29731169) 		K	0					
N60P48	gp120 CD4i CoRbs (Cluster C)		N60	N60 lineage 5	Sajadi2018(29731169) 		K	0					
N60P51	gp120 CD4i CoRbs (Cluster C)		N60	N60 lineage 6	Sajadi2018(29731169) 		K	0					
N6/10E8v4-PGDM1400	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)		Donor 84,Donor N152,Z258		Xu2017(28931639) 			208		0.043305	6.74707		trispecific involving N6, PGDM1400, and 10E8
N6-LS	gp120 CD4bs		Z258		Julg2017(28539448) 			208		0.082206	5.06056		
N6/PGDM1400-10E8v4	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)		Donor 84,Donor N152,Z258		Xu2017(28931639) 			208		0.021634	6.46792	N6-LS/PGDM1400-10E8v4	trispecific involving N6, PGDM1400, and 10E8
NC37	quaternary structure		EB354		Freund2017(28100831) 		K	119		18.5195	15.2635	354NC37	
NC-Cow1	gp120 CD4bs	6PW6(BG505 SOSIP.664 in complex with 3 copies of NC-Cow1 Fab);EMD-20500(BG505 SOSIP.664 in complex with 3 copies of NC-Cow1 Fab);6OO0(bovine Fab NC-Cow1);6OPA(NC-Cow1 Fab in complex with HIV-1 BG505 SOSIP.664 and human Fabs 35022 and PGT128)	Cow #26		Sok2017(28726771) 	Mutation affects NC-Cow1 binding or neutralization		140		0.52253	44.4645		
NC-Cow10			Cow #26		Sok2017(28726771) 			23		0.46565	53.6086		
NC-Cow2	gp120 CD4bs		Cow #26		Sok2017(28726771) 			23		0.049206	13.527		NC-Cow2 is an orphan heavy chain, paired with a germline light chain
NC-Cow3			Cow #26		Sok2017(28726771) 			23		69.1312	2.84003		NC-Cow3 is an orphan heavy chain, paired with a germline light chain
NC-Cow4			Cow #26		Sok2017(28726771) 			23		33.0331	11.8105		
NC-Cow5			Cow #26		Sok2017(28726771) 			23		79.3854	2.11641		
NC-Cow6			Cow #26		Sok2017(28726771) 			23		35.7453	9.61165		
NC-Cow7			Cow #26		Sok2017(28726771) 			23		1.0281	62.7872		
NC-Cow8			Cow #26		Sok2017(28726771) 			23		1.0671	43.4132		
NC-Cow9			Cow #26		Sok2017(28726771) 			23		2.77506	21.5423		
NIH45-46	gp120 CD4bs	5D9Q(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46);4JDT(chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 (93TH057));3U7W(Fab NIH45-46);3U7Y(Fab NIH45-46 complexed with gp120);4JDV(germ-line precursor of NIH45-46 Fab);5IGX(NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120)	NIH45	VRC01	Scheid2011(21764753) 	hypervariable loop characteristic correlations with bNAb sensitivity;Mutations allowing binding of germline Abs;NIH45-46 contacts;NIH45-46 signature predictions;Signature Analysis Summary;Signature Analysis Summary	K	299	Yes	0.3131	15.4679	45, 45-46	
NIH45-46G54F	gp120 CD4bs		NIH45	VRC01	Diskin2011(22033520) 		K	82		0.13264	26.3472	45-46F	
NIH45-46G54W	gp120 CD4bs		NIH45	VRC01	Diskin2011(22033520) 	NIH45-46G54W mutations causing resistance;NIH45-46(G54W) signature predictions;Signature Analysis Summary	K	240		0.081064	45.5701	45-46W, NIH45-46 G54W, NIH45-46W	
NIH45-46G54Y	gp120 CD4bs		NIH45	VRC01	Diskin2011(22033520) 		K	82		0.1378	23.9373	45-46Y	
NIH45-46WPY	gp120 CD4bs		NIH45	VRC01		Signature Analysis Summary	K	118		0.026926	16.037	NIH45-46-WPY	
NIH45-46WY	gp120 CD4bs		NIH45	VRC01		Signature Analysis Summary	K	118		0.028743	15.8862	NIH45-46-WY	
PCDN-33A	gp120 V3 // V3 glycan (V3g)		PC76		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs		133		6.08665	25.6639	33A	
PCDN-38A	gp120 V3 // V3 glycan (V3g)		PC76		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs	K	133		13.1102	20.1397	38A, PCDN38A	
PCDN-38B	gp120 V3 // V3 glycan (V3g)		PC76		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs		133		7.50007	22.2127	38B	
PCT64-18B	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		44.1335	8.39332	PCT64 18B	
PCT64-18C	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		77.3056	2.91181	PCT64 18C	
PCT64-18D	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	123		21.5607	17.099	PCT64 18D	
PCT64-18F	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		34.8927	10.6058	PCT64 18F	
PCT64-24A	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		44.5511	7.00016	PCT64 24A	
PCT64-24B	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		48.978	6.20823	PCT64 24B	
PCT64-24E	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	122		21.4424	16.4408	PCT64 24E	
PCT64-24F	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	122		23.3356	17.7261	PCT64 24F	
PCT64-24G	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		36.6103	9.57143	PCT64 24G	
PCT64-24H	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		48.4913	6.57433	PCT64 24H	
PCT64-35B	gp120 V2 // V2 glycan(V2g) // V2 apex	5FEH(PCT64_35B, a broadly neutralizing anti-HIV antibody)	PC64	PCT64	Landais2017(29166592) 		K	122		22.2694	12.2215	PCT64 35B	
PCT64-35C	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		28.4326	12.8153	PCT64 35C	
PCT64-35D	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	122		19.795	12.9663	PCT64 35D	
PCT64-35E	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		27.6653	13.9691	PCT64 35E	
PCT64-35F	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		34.1535	10.208	PCT64 35F	
PCT64-35G	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	122		26.0402	10.2531	PCT64 35G	
PCT64-35H	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		41.4128	6.6585	PCT64 35H	
PCT64-35I	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		85.5159	1.92827	PCT64 35I	
PCT64-35K	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		39.2351	9.58151	PCT64 35K	
PCT64-35M	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	123		16.3071	19.49	PCT64 35M	
PCT64-35N	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	37		45.7088	7.35153	PCT64 35N	
PCT64-35O	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	122		29.9539	10.9467	PCT64 35O	
PCT64-35S	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64	PCT64	Landais2017(29166592) 		K	123		19.0401	15.5769	PCT64 35S	
PG16	gp120 V2 // V2 glycan(V2g) // V2 apex	4DQO(Fab PG16 complexed with V1V2 region (ZM109));3MUG(PG16 Fab);3MME(Structure and functional dissection of PG16);3LRS(Structure of PG16)	Donor 24	PG9	Walker2009a(19729618) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization;Mutation affects neutralization of PGDM1400 and PG16;Mutation affects PG9-like Ab sensitivity;Mutations at the trimer apex that affect sensitivity;PG16 signature predictions;PG9-like antibodies require N160 for neutralization;PG9-like contacts;V2 Signature Analysis Summary	L	818	Yes	0.67427	39.1648		
PG16/10-1074	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 17,Donor 24		Bournazos2016(27315478) 			33		0.26292	14.491		bispecific
PG16-iMab	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R		Donor 24		Pace2013a(23878231) 			134		0.0047604	15.7096	PG16-ibalizumab	bispecific
PG16/PGT121	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 17,Donor 24		Bournazos2016(27315478) 			116		0.30227	19.4428		bispecific
PG16/PGT128	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 24,Donor 36		Bournazos2016(27315478) 			117		0.30595	20.1815		bispecific
PG9	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5VJ6(BG505 SOSIP.664 in complex with PG9 and 8ANC195);3U36(Fab PG9);3U4E(Fab PG9 complexed with V1V2 region (CAP45));3U2S(Fab PG9 complexed with V1V2 region (ZM109));3MUH(PG9 light chain)	Donor 24	PG9	Walker2009a(19729618) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;Mutations at the trimer apex that affect sensitivity;PG9 contacts;PG9 escape mutations;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PG9 residue prediction;PG9 signature predictions;V2 Signature Analysis Summary	L	1017	Yes	0.86779	23.4433		
PG9/aplaviroc	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CCR5		Donor 24		Gavrilyuk2013(23427154) 			117		0.33288	7.99799	PG9-aplaviroc	Conjugation of PG9 with aplaviroc, a small molecule that blocks CCR5.
PG9-iMab	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R		Donor 24		Pace2013a(23878231) 			141		0.0073056	8.86025	PG9-ibalizumab	bispecific
PG9-PG16-RSH	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 24	PG9	Pancera2013(23708607) 		L	212		0.2509	50.5214	PG9-16, PG916, PG9-16-RSH	chimeric
PGC14	gp120		Donor 24		Walker2009a(19729618) 		L	162		76.5847	2.73307		
PGDM11	gp120 V3 // V3 glycan (V3g)		Donor 14		Sok2016(27438765) 			110		7.71323	21.8645		
PGDM12	gp120 V3 // V3 glycan (V3g)		Donor 14		Sok2016(27438765) 			134		2.84353	33.9304		
PGDM1400	gp120 V2 // V2 glycan(V2g) // V2 apex	4RQQ(Fab PGDM1400)	Donor 84		Sok2014(25422458) 	Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization of PGDM1400 and PG16;Mutation causes resistance to V2 bnAbs;PGDM1400 lineage requires N160;V2 Signature Analysis Summary	K	846		0.18556	61.017		
PGDM1400-LS	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84					208		0.13842	55.316		
PGDM1400/PRO-140	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CCR5		Donor 84		Khan2018(29976677) 			107		0.032683	19.2107	PGDM1400fv-PRO-140fv	
PGDM1401	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84		Sok2014(25422458) 	PGDM1400 lineage requires N160	K	107		0.29088	116.019		
PGDM1402	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84		Sok2014(25422458) 	PGDM1400 lineage requires N160	K	102		10.0606	17.8356		
PGDM1403	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84		Sok2014(25422458) 	PGDM1400 lineage requires N160	K	98		6.3626	43.7463		
PGDM1404	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84		Sok2014(25422458) 	PGDM1400 lineage requires N160	K	88		8.06011	47.5202		
PGDM1405	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84		Sok2014(25422458) 	PGDM1400 lineage requires N160	K	98		11.3345	50.3411		
PGDM1406	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84		Sok2014(25422458) 	PGDM1400 lineage requires N160	K	88		53.9685	5.52324		
PGDM21	gp120 V3 // V3 glycan (V3g)	EMD-8182(PGDM21 in complex with BG505 SOSIP.664 trimer)	Donor 82		Sok2016(27438765) 			134		4.44153	34.488		
PGG14	gp120		Donor 24		Walker2009a(19729618) 		L	0					
PGT121	gp120 V3 // V3 glycan (V3g)	5CEZ(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with an early putative precursor of the PGT121 family);4JY4(Fab PGT121);4FQQ(germline antibody PGT121-GL Fab);4FQ1(PGT121 Fab);4FQC(PGT121 Fab bound to a complex-type sialylated N-glycan)	Donor 17	PGT121	Walker2011(21849977) 	Disulfide bond introduced in V1V2 affects binding;hypervariable loop characteristic correlations with bNAb sensitivity;Key sites for PGT121-like and 10-1074-like mAbs;Mutation affects neutralization of V3 mAbs;Mutation greatly reduces PGT121 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 contacts;PGT121 family and N137 glycan;PGT121 resistance;PGT121 signature predictions;V3 Signature Summary	L	1361	Yes	0.65073	52.8689	PGT-121	
PGT121.414.LS	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121				208		1.16397	66.6423		
PGT121GM	gp120 V3 // V3 glycan (V3g)		Donor 17	PGT121	Mouquet2012a(23115339) 			26		41.818	6.17672		
PGT122	gp120 V3 // V3 glycan (V3g)	5UTF(BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22);4NCO(BG505 in complex with Fab PGT122);5U7M(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22);5U7O(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);5D9Q(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5UTY(DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);4JY5(Fab PGT122);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122)	Donor 17	PGT121	Walker2011(21849977) 	Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;PGT122 glycan contacts;PGT122 neutralization	L	164		1.2886	45.8654	PGT-122	
PGT123	gp120 V3 // V3 glycan (V3g)	4JY6(Fab PGT123)	Donor 17	PGT121	Walker2011(21849977) 	Mutation greatly reduces PGT123 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;V3 Signature Analysis Summary	L	290		0.99835	65.0371	PGT-123	
PGT124	gp120 V3 // V3 glycan (V3g)	4R2G(PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4);5UM8(trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124);5T3S(trimer MD39-10MUTA in complex with Fabs PGT124 and 35022)	Donor 17	PGT121	Walker2011(21849977) 	PGT121 family and N137 glycan	L	86		0.14027	19.4097	PGT-124	
PGT125	gp120 V3 // V3 glycan (V3g)		Donor 36	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT125 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary	L	273		3.1199	60.4455	PGT-125	
PGT126	gp120 V3 // V3 glycan (V3g)		Donor 36	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT126 and PGT127 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary	L	434	Yes	0.94013	46.6816	PGT-126	
PGT127	gp120 V3 // V3 glycan (V3g)	3TWC(PGT127 complexed with Man(9))	Donor 36	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT126 and PGT127 neutralization;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;V3 Signature Analysis Summary	L	272		4.87851	37.5113	PGT-127	
PGT128	gp120 V3 // V3 glycan (V3g)	5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);6OPA(bovine Fab NC-Cow1 in complex with BG505 SOSIP.664 and human Fabs 35022 and PGT128);5JSA(gp140 trimer with an engineered 10-residue HR1 turn bound to 8ANC195 and PGT128);5JS9(gp140 trimer with an engineered 8-residue HR1 turn bound to 8ANC195 and PGT128);3TYG(PGT128 complexed with glycosylated gp120);3TV3(PGT128 complexed with Man(9));5ACO(PGT128 Fab in complex with BG505 SOSIP.664 Env trimer);6B3D(PGT128 in complex with a bacterially derived synthetic mimetic of Man9)	Donor 36	PGT128	Walker2011(21849977) 	hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects neutralization of V3 mAbs;Mutation greatly reduces PGT128 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;PGT128 contacts;PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO);V3 Signature Analysis Summary	L	726		0.84397	59.8929	PGT-128	
PGT128-IgG3C-	gp120 V3 // V3 glycan (V3g)		Donor 36	PGT128	Bournazos2016(27315478) 			116		0.84187	53.0508		IgG3C hinge variant
PGT130	gp120 V3 // V3 glycan (V3g)		Donor 36	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT130 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary	L	308		3.16688	36.2058	PGT-130	
PGT131	gp120 V3 // V3 glycan (V3g)		Donor 36	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization	L	162		11.0186	21.2576	PGT-131	
PGT135	gp120 V3 // V3 glycan (V3g)	4JM4(Fab PGT135);4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab)	Donor 39	PGT135	Walker2011(21849977) 	Mutation greatly reduces PGT135 neutralization;Mutations at the trimer apex that affect sensitivity;PGT135 contacts and sites;V3 Signature Analysis Summary	K	510		14.8308	19.4218	PGT-135	
PGT135-IgG3C-	gp120 V3 // V3 glycan (V3g)		Donor 39	PGT135	Bournazos2016(27315478) 			119		19.8045	16.7842		IgG3C hinge variant
PGT136	gp120 V3 // V3 glycan (V3g)		Donor 39	PGT135	Walker2011(21849977) 		K	164		54.5814	5.82733	PGT-136	
PGT137	gp120 V3 // V3 glycan (V3g)		Donor 39	PGT135	Walker2011(21849977) 		K	162		40.3483	8.18728	PGT-137	
PGT141	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		Donor 84	PGT145	Walker2011(21849977) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	K	186		4.13098	34.5902	PGT-141	
PGT142	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		Donor 84	PGT145	Walker2011(21849977) 	hypervariable loop characteristic correlations with bNAb sensitivity;V2 Signature Analysis Summary;V2 Signature Analysis Summary	K	344		1.78526	70.1417	PGT-142	
PGT143	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5UXQ(Structure of PGT143)	Donor 84	PGT145	Walker2011(21849977) 	Mutation causes resistance to V2 bnAbs;Mutation greatly reduces PGT143 neutralization;V2 Signature Analysis Summary	K	274		3.55651	38.5754	PGT-143	
PGT144	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5UY3(Structure of human Fab PGT144)	Donor 84	PGT145	Walker2011(21849977) 		K	162		20.9877	10.5939	PGT-144	
PGT145	gp120 V2 // V2 glycan(V2g) // V2 apex	5U1F(BG505 DS-SOSIP trimer in complex with CD4 and antibody PGT145);5V8L(BG505 SOSIP.664 trimer in complex with 3BNC117 and PGT145);3U1S(Fab PGT145);6NIJ(PGT145 Fab in complex with full length AMC011 Env)	Donor 84	PGT145	Walker2011(21849977) 	Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;Mutation causes resistance to V2 bnAbs;Mutation greatly reduces PGT145 neutralization;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PGT145 contacts;PGT145 epitope;PGT145 escape mutations;Signature Analysis Summary;V2 Signature Analysis Summary	K	748		0.96985	39.8068	PGT-145	
PGT151	fusion peptide // near gp41-gp120 interface	4NUG(Antibody PGT151);EMD-0620(Full length HIV-1 Envelope glycoprotein AMC011 in complex with PGT151 Fab and PGZL1 Fab);5FUU(JR-FL EnvdCT trimer in complex with PGT151 Fab);6DCQ(Wild type HIV-1 glycoprotein PC64M18C043 in complex with PGT151 Fab)	Donor 31		Falkowska2014(24768347) 	Mutation affects PGT151 neutralization;Mutation affects VRC01, PGT151, and 2G12 binding;PGT151-PGT158 sites of interaction	K	316	Yes	0.23202	79.9071	PGT-151	
PGT151/10-1074-IgG3C-	fusion peptide // near gp41-gp120 interface;gp120 V3 // V3 glycan (V3g)		Donor 17,Donor 31		Bournazos2016(27315478) 			119		0.12608	23.6649		bispecific; IgG3C hinge variant
PGT151/35O22	fusion peptide // near gp41-gp120 interface;gp41-gp120 interface		Donor 31,Donor N152		Bournazos2016(27315478) 			120		1.18454	26.2946		bispecific
PGT151-IgG3C-	fusion peptide // near gp41-gp120 interface		Donor 31		Bournazos2016(27315478) 			119		0.42059	65.6104		IgG3C hinge variant
PGT152	fusion peptide // near gp41-gp120 interface	4NUJ(Antibody PGT152)	Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	116	Yes	0.47199	75.5425	PGT-152	
PGT153	gp41		Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	25		6.87459	34.5845	PGT-153	
PGT154	gp41		Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	25		4.0906	44.6074	PGT-154	
PGT155	gp41		Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	25		4.88956	47.1451	PGT-155	
PGT156	gp41		Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	25		3.83441	62.2493	PGT-156	
PGT157	gp41		Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	25		9.82692	30.9537	PGT-157	
PGT158	gp41		Donor 31		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	K	25		4.88464	50.9387	PGT-158	
PGZL1	gp41 MPER (membrane proximal external region)	6O3D(Fab fragment of PGZL1);6O3G(Fab fragment of PGZL1 in complex with its MPER peptide epitope);6O3J(Fab fragment of PGZL1 in complex with its MPER peptide epitope and phosphatidic acid);EMD-0620(Full length HIV-1 Envelope glycoprotein AMC011 in complex with PGT151 Fab and PGZL1 Fab)	PG13	PGZL1	Zhang2019a(31772165) 	Mutation affects neutralization by PGZL1, H4K3, or 4E10;PGZL1 contacts	K	130		9.59677	6.16393		
PGZL1_gVmDmJ	gp41 MPER (membrane proximal external region)	6O42(germline PGZL1 (PGZL1_gVmDmJ) Fab in complex with MPER peptide epitope);6O41(PGZL1 germline Fab fragment PGZL1_gVmDmJ)	PG13	PGZL1	Zhang2019a(31772165) 		K	130		75.6029	2.38435	PGZL1 gVmDmJ	
PGZL1.H4K3	gp41 MPER (membrane proximal external region)	6O3K(Fab fragment of PGZL1.H4K3);6O3U(Fab fragment of PGZL1.H4K3 in complex with 06:0 PA);6O3L(Fab fragment of PGZL1.H4K3 in complex with its MPER peptide epitope)	PG13	PGZL1	Zhang2019a(31772165) 	Mutation affects neutralization by PGZL1, H4K3, or 4E10	K	130		1.4267	4.66656	H4K3	
polyclonal 391370	gp120 CD4bs		391370		Barnes2022(35960796) 			21		90.2876	1.2914		
polyclonal AIIMS_329 102mo			AIIMS_329		Mishra2019(31217240) 			43					
polyclonal AIIMS_329 112mo			AIIMS_329		Mishra2019(31217240) 			45					
polyclonal AIIMS_329 117mo			AIIMS_329		Mishra2019(31217240) 			45					
polyclonal AIIMS_329 124mo			AIIMS_329		Mishra2019(31217240) 			43					
polyclonal AIIMS_329 131mo			AIIMS_329		Mishra2019(31217240) 			43					
polyclonal AIIMS_329 138mo			AIIMS_329		Mishra2019(31217240) 			43					
polyclonal AIIMS_329 78mo			AIIMS_329		Mishra2019(31217240) 			43					
polyclonal AIIMS_329 82mo			AIIMS_329		Mishra2019(31217240) 			43					
polyclonal AIIMS_329 90mo			AIIMS_329		Mishra2019(31217240) 			45					
polyclonal AIIMS_330 102mo			AIIMS_330		Mishra2019(31217240) 			43					
polyclonal AIIMS_330 112mo			AIIMS_330		Mishra2019(31217240) 			46					
polyclonal AIIMS_330 117mo			AIIMS_330		Mishra2019(31217240) 			47					
polyclonal AIIMS_330 124mo			AIIMS_330		Mishra2019(31217240) 			43					
polyclonal AIIMS_330 131mo			AIIMS_330		Mishra2019(31217240) 			43					
polyclonal AIIMS_330 138mo			AIIMS_330		Mishra2019(31217240) 			43					
polyclonal AIIMS_330 78mo			AIIMS_330		Mishra2019(31217240) 			43					
polyclonal AIIMS_330 82mo			AIIMS_330		Mishra2019(31217240) 			43					
polyclonal AIIMS_330 90mo			AIIMS_330		Mishra2019(31217240) 			45					
polyclonal AIIMS704			AIIMS704		Mishra2020a(32879304) 			12					
polyclonal AIIMS706			AIIMS706		Mishra2020a(32879304) 			12					
polyclonal AIIMS709			AIIMS709		Mishra2020a(32879304) 			12					
polyclonal AIIMS731			AIIMS731		Mishra2020(32669335) 			18					
polyclonal AIIMS743			AIIMS743		Mishra2020a(32879304) 			12					
polyclonal BF520	gp120 V3 // V3 glycan (V3g)		BF520		Simonich2016(27345369) 			34					
polyclonal CAP206	gp41 MPER (membrane proximal external region)		CAP206		Gray2009a(19692477) 			34					
polyclonal CAP248	fusion peptide // near gp41-gp120 interface		CAP248		Wibmer2017(28076415) 			35					
polyclonal CAP256 Year1			CAP256		Moore2011(21270156) 			31				CAP256 plasma wk59	
polyclonal CAP256 Year2			CAP256		Moore2011(21270156) 			31				CAP256 plasma wk106	
polyclonal CAP256 Year3			CAP256		Moore2011(21270156) 			31				CAP256 plasma wk159	
polyclonal CAP256 Year4			CAP256		Moore2011(21270156) 			31				CAP256 plasma wk220	
polyclonal CBJC438 3/2008			CBJC438		Kumar2020(32938661) 			12					
polyclonal CBJC515 2005			CBJC515		Li2016(26671829) 			51					
polyclonal CBJC515 2006			CBJC515		Hu2021(33805985) 			28					
polyclonal CBJC515 2008	gp120 CD4bs		CBJC515		Hu2021(33805985) 			28					
polyclonal CH0457 wk8			CH0457		Moody2015(26355218) 			47					
polyclonal CH0457 wk96			CH0457		Moody2015(26355218) 			39					
polyclonal Cow26 d238			Cow #26		Sok2017(28726771) 			117					
polyclonal Cow26 d381			Cow #26		Sok2017(28726771) 			117					
polyclonal Cow26 d42			Cow #26		Sok2017(28726771) 			117					
polyclonal Cow26 d77			Cow #26		Sok2017(28726771) 			117					
polyclonal Donor 17			Donor 17		Walker2011(21849977) 			162					
polyclonal Donor 24			Donor 24		Walker2009a(19729618) 			162					
polyclonal Donor 27845			27845		Schoofs2019(31126879) 			31		84.0426	1.28112		
polyclonal Donor 31			Donor 31		Walker2010(20700449) 			25					
polyclonal Donor 36			Donor 36		Walker2011(21849977) 			162					
polyclonal Donor 39			Donor 39		Walker2011(21849977) 			162					
polyclonal Donor 74			Donor 74		Zhou2018(29548671) 			22					
polyclonal Donor 84			Donor 84		Walker2011(21849977) 			162					
polyclonal DRVI01 2005-07			DRVI01		Kong2016(27067056) 			63				polyclonal DRVI01 7/2005	
polyclonal DRVI01 2005-10			DRVI01		Kong2016(27067056) 			63				polyclonal DRVI01 10/2005	
polyclonal DRVI01 2006-04			DRVI01		Kong2016(27067056) 			63				polyclonal DRVI01 4/2006	
polyclonal DRVI01 2006-11			DRVI01		Kong2016(27067056) 			37				polyclonal DRVI01 11/2006	
polyclonal DRVI01 2007-04			DRVI01		Kong2016(27067056) 			37				polyclonal DRVI01 4/2007	
polyclonal DRVI01 2008-03			DRVI01		Kong2016(27067056) 			63				polyclonal DRVI01 3/2008	
polyclonal DRVI01 2008-12			DRVI01		Kong2016(27067056) 			37				polyclonal DRVI01 12/2008	
polyclonal DRVI01 2009-05			DRVI01		Kong2016(27067056) 			37				polyclonal DRVI01 5/2009	
polyclonal DRVI01 2009-12			DRVI01		Kong2016(27067056) 			63				polyclonal DRVI01 12/2009	
polyclonal EB179	gp120 CD4bs		EB179		Freund2015(26516768) 			14		79.9672	1.54648		
polyclonal IDC561			IDC561		Schommers2020(32004464) 			38		56.2654	1.93335		
polyclonal N152			Donor N152		Huang2012(22192629) 			177					
polyclonal NIH45			NIH45		Wu2010(20616233) 			139		73.2555	1.74608		
polyclonal Patient 1			Patient 1		Scheid2011(21764753) 			21		79.7209	1.6126		
polyclonal Patient 12			Patient 12		Scheid2011(21764753) 			6					
polyclonal Patient 3			Patient 3		Scheid2011(21764753) 			38		65.8404	2.00908		
polyclonal Patient 8			Patient 8		Scheid2011(21764753) 			21		59.3104	2.33271		
polyclonal PC64-M35			PC64		Landais2017(29166592) 			123					
polyclonal pt7 IgA			pt7		Lorin2022(35230385) 			24		61.5825	3.41285		
polyclonal pt7 IgG			pt7		Lorin2022(35230385) 			24		59.3504	3.30053		
polyclonal QA013	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 			33					
polyclonal R1			R1		Gristick2016(27617431) 			18		70.0696	1.84216		
PRO-140	non-HIV: host CCR5				Olson1999(10196311) 			106		0.33411	4.05364	P140, PA14, PRO 140	
PRO-140/PGDM1400/PGT121	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);non-HIV: host CCR5		Donor 17,Donor 84		Khan2018(29976677) 			105		0.054149	16.0618	PRO140Fab-PGDM1400fv-PGT121fv	trispecific
QA013.19	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 		L	19		37.6701	5.78481		
QA013.2	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 		L	33		10.861	16.0538		
QA013.3	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 		L	19		34.6598	10.6183		
QA013.32	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 		L	19		30.6613	8.13293		
QA013.4	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 		L	19		31.8265	7.69202		
QA013.53	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013		Williams2018(29669274) 		L	18		29.6894	12.3924		
QA255.087			QA255		Williams2015(26629541) 		K	9	No				
QA255.105	gp120 V3 // V3 glycan (V3g)		QA255		Williams2015(26629541) 		K	9	Yes				
QA255.157	gp120 CD4i cluster A		QA255		Williams2015(26629541) 		K	0	Yes				
QA255.187			QA255		Williams2015(26629541) 		K	9	No				
QA255.253	gp120 CD4i cluster A		QA255		Williams2015(26629541) 		K	0	Yes				
RoAb13	non-HIV: host CCR5				Ji2007(17166600) 			106		0.30728	9.45136	ROAb13	
RoAb13/PGDM1400/PGT121	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);non-HIV: host CCR5		Donor 17,Donor 84		Khan2018(29976677) 			107		0.094815	24.9301	RoAb13Fab-PGDM1400fv-PGT121fv	
RoAb13/PRO-140	non-HIV: host CCR5				Khan2018(29976677) 			106		0.2401	2.55389	RoAb13/PRO 140	bispecific
sCD4		1CDJ(glycoprotein CD4);1GC1(gp120 core complexed with CD4 and 17b);1G9M(gp120 (HXB2) complexed with CD4 and 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b)						459		7.30769	5.01651		
SF10	gp120 silent face		27845	SF12	Schoofs2019(31126879) 		K	31		3.33066	43.1113		
SF12	gp120 silent face	EMD-20100(B41 SOSIP.664 in complex with SF12 and 10-1074);EMD-20101(B41 SOSIP.664 trimer in complex with 2 Fab fragments of SF12 and 1 Fab fragment of 10-1074);6OKQ(SF12 Fab);6OKP(SOSIP.664 in complex with SF12 and 10-1074)	27845	SF12	Schoofs2019(31126879) 	SF12 interaction sites	K	138		2.12886	26.5461		
SF2	gp120 silent face		27845	SF12	Schoofs2019(31126879) 		K	31		21.2102	16.2415	SF02	
SF3	gp120 silent face		27845	SF12	Schoofs2019(31126879) 		K	31		16.7942	20.2421	SF03	
SF5	gp120 silent face		27845	SF12	Schoofs2019(31126879) 		K	138		3.17704	30.2375	SF05	
SF7	gp120 silent face		27845	SF12	Schoofs2019(31126879) 		K	31		16.1502	21.7268	SF07	
SF8	gp120 silent face		27845	SF12	Schoofs2019(31126879) 		K	31		21.3329	17.876	SF08	
Tri-NAb	gp120 CD4bs;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17,Donor N152,NIH45		Steinhardt2018(29491415) 			208		0.071679	6.29224		trispecific involving VRC01, PGT121, and 10E8
vFP1.01	gp41 fusion domain	5TKJ(vFP1.01 in complex with HIV-1 fusion peptide residue 512-519)	1868		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs		208		78.9308	2.30044	1868-vFP1.01	mouse Ab
vFP16.02	gp41 fusion domain	6CDO(vFP16.02 in complex with HIV-1 fusion peptide residue 512-519)	2712		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs		208		37.5988	5.70298	2712-vFP16.02	mouse Ab
vFP20.01	gp41 fusion domain	6CDP(vFP20.01 in complex with HIV-1 fusion peptide residue 512-519)	2716		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs		208		44.3829	4.52989	2716-vFP20.01	mouse Ab
vFP5.01	gp41 fusion domain	5TKK(vFP5.01 in complex with HIV-1 fusion peptide residue 512-519)	1868		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs		208		98.4733	1.14622	1868-vFP5.01	mouse Ab
vFP7.04	gp41 fusion domain	6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122);6CDM(vFP7.04 in complex with HIV-1 fusion peptide residue 512-519)	2586		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs		208		78.8731	2.2905	2586-vFP7.04	mouse Ab
vFP7.05	gp41 fusion domain		2586		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs		208		83.1511	2.09128	2586-vFP7.05	mouse Ab
VRC01	gp120 CD4bs	6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);4JPI(Fab VRC01 germline precursor);6MYY(Germline VRC01 antibody recognition of a modified clade C envelope trimer);5KZC(gp120 engineered outer domain with a Man9 glycan at position N276, in complex with VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);3NGB(VRC01 complexed with gp120);4LSS(VRC01 complexed with gp120 (KER2008));4LST(VRC01 complexed with gp120 (ZM176));4JPK(VRC01 germline precursor Fab complexed with gp120 outer domain)	NIH45	VRC01	Wu2010(20616233) 	Electrostatic interactions with D368;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation abrogates BG24 OR VRC01 neutralization;Mutation affects neutralization;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation affects VRC01 neutralization;Mutation affects VRC01, PGT151, and 2G12 binding;Mutation decreases binding to CD4BS mAbs;Mutations allowing binding of germline Abs;Mutations associated with immunotherapy with BG24 or VRC01;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01;Sequence changes after immunotherapy with VRC01;Signature Analysis Summary;VRC01 alanine scanning;VRC01 contacts;VRC01 residue prediction;VRC01 signature predictions	K	1325	Yes	0.86674	9.94655	VRC01 d45, VRC-HIVMAB060-00-AB	
VRC01-0fH/0fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		100	1		
VRC01.23LS	gp120 CD4bs	6VI0(VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP);EMD-21208(VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP)	NIH45	VRC01	Kwon2021(34328065) 	VRC01.23LS primary contacts	K	208		0.058173	7.34675		
VRC01-30fH/10fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.116	6.59213		
VRC01-30fH/19fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.24418	6.15972		
VRC01-5fH/0fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		48.8246	6.57282		
VRC01-5fH/10fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.47302	7.52701		
VRC01-5fH/6fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.4139	9.21114		
VRC01-8fH/10fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.48875	8.77056		
VRC01-8fH/19fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.95145	7.28841		
VRC01-8fH/6fL	gp120 CD4bs		NIH45	VRC01	Georgiev2014(24391217) 			21		0.86517	7.89262		
VRC01b	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01c	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01d	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01e	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01-E16A(HC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01-E28T(HC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01f	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01g	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01h	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01H-DRVIA7L	gp120 CD4bs		DRVI01,NIH45		Kong2016(27067056) 		K	37		92.7804	1.5677	VRC01H+ DRVIA7L	
VRC01i	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC01-I21L(LC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01-LS	gp120 CD4bs		NIH45	VRC01	Ko2014(25119033) 		K	208	Yes	0.46537	9.01353	VRC01LS	
VRC01-N73T(LC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01-P63K(HC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01/PGDM1400-10E8v4	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)		Donor 84,Donor N152,NIH45		Xu2017(28931639) 			208		0.039266	9.30439	SAR-441236, SAR441236, VRC01-LS/PGDM1400-10E8v4	trispecific involving VRC01, PGDM1400, and 10E8
VRC01 UCA	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	14		100	1		
VRC01-W68S(LC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01-Y28S(LC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC01-Y72F(LC)	gp120 CD4bs		NIH45	VRC01	Wiehe2018(29861171) 		K	3					
VRC02	gp120 CD4bs		NIH45	VRC01	Wu2010(20616233) 	VRC02 signature predictions	K	213		0.52135	8.81276		
VRC03	gp120 CD4bs	EMD-8981(2G12 bound to HIV-1 Env BG505 DS-SOSIP which was also bound to VRC03);6E5P(2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to VRC03);5JXA(Ligand-free VRC03 antigen-binding fragment);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122);3SE8(VRC03 complexed with gp120);5JOF(VRC03 gHVgLV antigen-binding fragment)	NIH45	VRC01 (VRC03+06 sublineage)	Wu2010(20616233) 	Altered glycosylation affects neutralization by CD4BS bnAbs;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary;VRC03 contacts;VRC03 signature predictions	K	374		6.45245	21.9965	VRC03 d45	
VRC03b	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12				VRC03b	
VRC03d	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12				VRC03d	
VRC03f	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12				VRC03f	
VRC03g	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12				VRC03g	
VRC03h	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12				VRC03h	
VRC03i	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12				VRC03i	
VRC06	gp120 CD4bs	4JB9(VRC06 in complex with HIV-1 gp120 core)	NIH45	VRC01 (VRC03+06 sublineage)	Li2012(22875963) 		K	189		23.8065	9.61119		
VRC06b	gp120 CD4bs	4XNZ(VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120)	NIH45	VRC01 (VRC03+06 sublineage)	Li2012(22875963) 	Signature Analysis Summary	K	236		9.88935	19.7585	VRC06b	
VRC06c	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12					
VRC06d	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12					
VRC06e	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12					
VRC06f	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12					
VRC06g	gp120 CD4bs		NIH45	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 		K	12					
VRC07	gp120 CD4bs	4OLV(VRC07-G54F in complex with 93TH057 gp120);4OLW(VRC07-G54H in complex with 93TH057 gp120);4OLX(VRC07-G54L in complex with 93TH057 gp120);4OLY(VRC07-G54R in complex with 93TH057 gp120);4OLZ(VRC07-G54W in complex with 93TH057 gp120);4OM0(VRC07-G54Y in complex with 93TH057 gp120);4OM1(VRC07-I30Q, G54W, S58N in complex with 93TH057 gp120);4OLU(VRC07 in complex with 93TH057 gp120)	NIH45	VRC01	Rudicell2014(25142607) 	hypervariable loop characteristic correlations with bNAb sensitivity;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary	K	399		0.29019	10.5786		
VRC07-501-LS	gp120 CD4bs		NIH45	VRC01	Rudicell2014(25142607) 		K	179		0.058126	10.6101		
VRC07-508-LS	gp120 CD4bs		NIH45	VRC01	Rudicell2014(25142607) 		K	179		0.069271	14.2131		
VRC07-523-F54-LS.v3	gp120 CD4bs		NIH45	VRC01	Kwon2021(34328065) 		K	208		0.035973	6.70863		
VRC07-523-LS	gp120 CD4bs		NIH45	VRC01	Rudicell2014(25142607) 	hypervariable loop characteristic correlations with bNAb sensitivity;Signature Analysis Summary;Signature Analysis Summary	K	411		0.082334	8.95176	VRC07-523, VRC07-523LS	
VRC07-523-W54-LS.v3	gp120 CD4bs		NIH45	VRC01	Kwon2021(34328065) 		K	207		0.030373	6.21709		
VRC07-544-LS	gp120 CD4bs		NIH45	VRC01	Rudicell2014(25142607) 		K	179		0.074032	10.9016		
VRC07b	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC07c	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC07d	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC07e	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC07f	gp120 CD4bs		NIH45	VRC01	Wu2015(25865483) 		K	12					
VRC07xPG9-16	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 24,NIH45		Asokan2015(26446600) 			22		0.025853	26.973		bispecific
VRC08	gp120 CD4bs	4XMP(VRC08 in complex with HIV-1 clade A strain Q842.d12 gp120)	NIH45	VRC01 (VRC08 sublineage)	Wu2015(25865483) 		K	203		0.25167	11.6464		
VRC08c	gp120 CD4bs		NIH45	VRC01 (VRC08 sublineage)	Wu2015(25865483) 		K	12					
VRC08d	gp120 CD4bs		NIH45	VRC01 (VRC08 sublineage)	Wu2015(25865483) 		K	12					
VRC08e	gp120 CD4bs		NIH45	VRC01 (VRC08 sublineage)	Wu2015(25865483) 		K	12					
VRC08H/UCAL	gp120 CD4bs		NIH45	VRC01	Bonsignori2018(30552024) 		K	14		9.66349	10.9214	VRC08H/UCAL	chimeric: VRC08 HC with VRC01-UCA LC
VRC13	gp120 CD4bs	4YDJ(44-VRC13.01 in complex with HIV-1 clade AE strain 93TH057 gp120)	44		Zhou2015(26004070) 	Signature Analysis Summary;VRC13 contacts	L	400		0.7001	21.6859	44-VRC13.01, VRC13.01	
VRC16	gp120 CD4bs	4YDK(C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120)	C38		Zhou2015(26004070) 	Signature Analysis Summary;VRC16 contacts;VRC16 contacts	K	242		10.1831	11.4287	C38-VRC16.01, VRC16.01	
VRC18	gp120 CD4bs	4YDL(C38-VRC18.02 in complex with HIV-1 clade AE strain 93TH057 gp120)	C38		Zhou2015(26004070) 	VRC18 contacts	K	175		4.60778	12.1397	C38-VRC18.02, VRC18.02	
VRC21.01	gp120 V3 // V3 glycan (V3g)		N170	VRC21	Longo2016(27654288) 		L	28		50.5423	6.41227		
VRC21.02	gp120 V3 // V3 glycan (V3g)		N170	VRC21	Longo2016(27654288) 		L	28		53.3922	5.01602		
VRC22.01	gp120 V3 // V3 glycan (V3g)		N170		Longo2016(27654288) 		K	208		79.9232	2.32598		
VRC23	gp120 CD4bs	4J6R(VRC23 in complex with HIV-1 gp120)	127/C		Georgiev2013(23661761) 		K	181		9.7537	9.06124		
VRC23b	gp120 CD4bs		127/C		Georgiev2013(23661761) 		K	25		2.36696	10.0325		
VRC24	gp120 V3 // V3 glycan (V3g)		N27		Georgiev2013(23661761) 	Mutations at the trimer apex that affect sensitivity	L	57		21.1932	14.2941		
VRC26.01	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OCR(Fab CAP256-VRC26.01)	CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	191		45.7262	6.77853	CAP256-VRC26.01	
VRC26.02	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		24.9844	17.091	CAP256-VRC26.02	
VRC26.03	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OD1(Fab CAP256-VRC26.03)	CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	203		5.92568	51.1265	CAP256-VRC26.03	
VRC26.04	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4ORG(Fab CAP256-VRC26.04)	CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		11.491	30.2338	CAP256-VRC26.04	
VRC26.05	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		14.6264	37.7645	CAP256-VRC26.05	
VRC26.06	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OCW(Fab CAP256-VRC26.06)	CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	206		52.2653	6.36854	CAP256-VRC26.06	
VRC26.07	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OD3(Fab CAP256-VRC26.07, a potent V1V2-directed HIV-1 neutralizing antibody)	CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		42.7516	11.2896	CAP256-VRC26.07	
VRC26.08	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations at the trimer apex that affect sensitivity;V2 Signature Analysis Summary	L	416		0.67925	146.319	CAP256-VRC26.08	
VRC26.09	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;Disulfide bond introduced in V1V2 affects binding and neutralization;VRC26.09 escape mutations	L	217		2.13866	98.1991	CAP256-09, CAP256.09, CAP256-VRC26.09	
VRC26.10	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OCS(Fab CAP256-VRC26.10)	CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		19.9435	18.0649	CAP256-VRC26.10	
VRC26.11	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		21.0456	16.7775	CAP256-VRC26.11	
VRC26.12	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	56		55.1423	6.21408	CAP256-VRC26.12	
VRC26.13	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		57.3671	6.91884	CAP256-VRC26.13	
VRC26.14	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		21.2703	21.9103	CAP256-VRC26.14	
VRC26.15	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		17.7778	18.5014	CAP256-VRC26.15	
VRC26.16	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		19.4692	21.7843	CAP256-VRC26.16	
VRC26.17	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		14.2809	29.361	CAP256-VRC26.17	
VRC26.18	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		21.2526	18.578	CAP256-VRC26.18	
VRC26.19	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		6.25411	30.6226	CAP256-VRC26.19	
VRC26.20	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;Selects for breadth-driven Abs in CAP256 lineages	L	48		92.4725	1.71003	CAP256-VRC26.20	
VRC26.21	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		38.5418	15.406	CAP256-VRC26.21	
VRC26.22	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		3.40475	67.4206	CAP256-VRC26.22	
VRC26.23	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		56.2467	7.82527	CAP256-VRC26.23	
VRC26.24	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	48		63.1294	5.52389	CAP256-VRC26.24	
VRC26.25	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	6VTT(CAP256-VRC26.25 Fab bound to HIV-1 Env trimer CAP256.wk34.c80 SOSIP.RnS2);5DT1(Fab CAP256-VRC26.25)	CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;V2 Signature Analysis Summary;VRC26.25 contacts;VRC26.25 neutralization associated sites	L	464		0.088676	227.135	CAP256-VRC26.25	
VRC26.25 D99E	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.028692	48.6146		
VRC26.25 D99E/E100bV	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.021264	33.6076		
VRC26.25 D99E/E100bV/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.016252	29.2692		
VRC26.25 D99E/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.024566	39.1178		
VRC26.25 E100bV	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.020886	38.8285		
VRC26.25 E100bV/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.015004	28.5054		
VRC26.25 E100bV/K100sR/L:S95bD	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.010432	44.5503		
VRC26.25 E100bV/Q100nE/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.0057805	37.8161		
VRC26.25.K100mA	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Zhang2022(36284200) 		L	208		0.36168	154.443	CAP256-VRC26.25.K100mA	
VRC26.25 K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.026497	38.644		
VRC26.25 R97G/D99V/E100bV	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256	VRC26	Yin2021(34261793) 		L	16		0.019888	39.5049		
VRC26.26	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;V2 Signature Analysis Summary	L	248		1.28959	87.6356	CAP256-VRC26.26	
VRC26.27	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	204		0.78118	138.474	CAP256-VRC26.27	
VRC26.28	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		2.56895	82.5635	CAP256-VRC26.28	
VRC26.29	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		2.81206	69.3584	CAP256-VRC26.29	
VRC26.30	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		10.0708	41.409	CAP256-VRC26.30	
VRC26.31	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		21.3807	27.306	CAP256-VRC26.31	
VRC26.32	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		24.7511	20.5688	CAP256-VRC26.32	
VRC26.33	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	L	53		23.192	20.9109	CAP256-VRC26.33	
VRC27	gp120 CD4bs	4YDI(Z258-VRC27.01 in complex with HIV-1 gp120 from clade A strain Q23.17)	Z258		Zhou2015(26004070) 	VRC27 alanine scanning;VRC27 contacts	K	179		1.08003	21.5606	VRC27.01, Z258-VRC27.01	
VRC28.01	gp120 V3 // V3 glycan (V3g)		N170		Longo2016(27654288) 		K	28		52.3467	6.37489		
VRC29.01	gp120 V3 // V3 glycan (V3g)		N170	VRC29	Longo2016(27654288) 		K	28		35.8774	10.0761		
VRC29.02	gp120 V3 // V3 glycan (V3g)		N170	VRC29	Longo2016(27654288) 		K	28		23.9047	11.3537		
VRC29.03	gp120 V3 // V3 glycan (V3g)		N170	VRC29	Longo2016(27654288) 		K	208		28.0365	9.06713		
VRC29.04	gp120 V3 // V3 glycan (V3g)		N170	VRC29	Longo2016(27654288) 		K	28		16.199	14.5892		
VRC34.01	fusion peptide // near gp41-gp120 interface	5I8C(BG505 Fusion Peptide in Complex with VRC34.01 Fab);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);5I8E(VRC34.01 Fab)	N123	VRC34	Kong2016a(27174988) 	Mutation affects neutralization by VRC34;Mutation reduces binding/neutralization of fusion peptide mAbs;Mutations affecting binding of VRC34.01 to fusion peptide epitope;VRC34.01 contacts;VRC34.01 mutations affect neutralization	K	219		4.59743	23.1548	N123-VRC34.01	
VRC34.02	fusion peptide // near gp41-gp120 interface		N123	VRC34	Kong2016a(27174988) 		K	22		1.87277	14.5418	N123-VRC34.02	
VRC34.03	fusion peptide // near gp41-gp120 interface		N123	VRC34	Kong2016a(27174988) 		K	22		14.9115	11.9376	N123-VRC34.03	
VRC34.04	fusion peptide // near gp41-gp120 interface		N123	VRC34	Kong2016a(27174988) 		K	22		16.5412	14.9627	N123-VRC34.04	
VRC34.05	fusion peptide // near gp41-gp120 interface		N123	VRC34	Kong2016a(27174988) 	VRC34.05 contacts	K	209		98.6298	1.21957	N123-VRC34.05	
VRC34.06	fusion peptide // near gp41-gp120 interface		N123	VRC34	Kong2016a(27174988) 		K	22		77.8393	3.15201	N123-VRC34.06	
VRC34.07	fusion peptide // near gp41-gp120 interface		N123	VRC34	Kong2016a(27174988) 		K	22		100	1	N123-VRC34.07	
VRC34-pI1	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	11				VRC34.01-pI1	Unpublished VRC34-pI1 info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953)
VRC34-pI2	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	11				VRC34.01-pI2	Unpublished VRC34-pI2 info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953)
VRC34-pI2'	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	11				VRC34.01-pI2'	Unpublished VRC34-pI2â info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953)
VRC34-pI2 H33P	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	11				VRC34.01-pI2 H33P	Unpublished info via personal communication (C. Shen) but related to Shen2020 (PMID 32130953)
VRC34-pI3	fusion peptide // near gp41-gp120 interface	6UCE(VRC34-pI3 with HIV fusion peptide residues 512-519)	N123	VRC34	Shen2020(32130953) 		K	209		3.92824	22.7977	VRC34.01-pI3	
VRC34-pI3'	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	11				VRC34.01-pI3'	Unpublished VRC34-pI3â info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953)
VRC34-pI3HCpI2LC	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	11				VRC34.01-pI3HCpI2LC	Chimera of pI3 HC and pI2 LC. Unpublished VRC34-pI2 info via personal communication (C. Shen) related to Shen2020 (PMID 32130953)
VRC34-pI4	fusion peptide // near gp41-gp120 interface	6UCF(VRC34-pI4 with HIV fusion peptide residues 512-519)	N123	VRC34	Shen2020(32130953) 		K	209		6.00755	21.0346	VRC34.01-pI4	
VRC34-UCA	fusion peptide // near gp41-gp120 interface		N123	VRC34	Shen2020(32130953) 		K	208		100	1	VRC34.01-UCA	Unpublished VRC34-UCA info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953)
VRC34YD.01	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		3.12972	10.735		
VRC34YD.02	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		11.6997	9.14855		
VRC34YD.03	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		5.57011	13.5579		
VRC34YD.04	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		4.45401	11.4055		
VRC34YD.05	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		7.22189	12.5243		
VRC34YD.06	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		4.8491	15.4402		
VRC34YD.07	fusion peptide // near gp41-gp120 interface		N123	VRC34	Wang2018(29309060) 			22		5.76716	12.7636		
VRC38.01	gp120 V2 // V2 glycan(V2g) // V2 apex	5EWI(Fab VRC38.01);5VGJ(Fab VRC38.01 bound to a scaffolded WITO V1V2 domain)	N90	VRC38	Cale2017(28514685) 	Mutation affects neutralization by V1V2 glycan mAbs;Mutations at the trimer apex that affect sensitivity;VRC38.01 contacts	K	246		18.6071	21.9897	N90-VRC38.01, VRC38	
VRC38.02	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		41.1956	11.3714	N90-VRC38.02	
VRC38.03	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		46.7849	6.35166	N90-VRC38.03	
VRC38.04	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		37.8086	11.7498	N90-VRC38.04	
VRC38.05	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		79.3197	3.55723	N90-VRC38.05	
VRC38.06	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		11.7522	28.1813	N90-VRC38.06	
VRC38.07	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		12.3217	29.2906	N90-VRC38.07	
VRC38.08	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	30		25.6964	10.557	N90-VRC38.08	
VRC38.09	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		18.8304	14.5252	N90-VRC38.09	
VRC38.10	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		34.5202	8.85779	N90-VRC38.10	
VRC38.11	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 		K	31		23.958	13.3844	N90-VRC38.11	
VRC38.12	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 			31		40.5342	8.4795	N90-VRC38.12	VRC38.12 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01.
VRC38.13	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 			31		18.4321	20.3122	N90-VRC38.13	VRC38.13 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01.
VRC38.14	gp120 V2 // V2 glycan(V2g) // V2 apex		N90	VRC38	Cale2017(28514685) 			31		23.4647	14.1259	N90-VRC38.14	VRC38.14 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01.
VRC41.01	gp120 V3 // V3 glycan (V3g)		CH765	VRC41	Alam2017(28298421) 	Mutation affects neutralization of V3 mAbs	K	127		4.93196	22.1047	CH765-VRC41.01	
VRC41.02	gp120 V3 // V3 glycan (V3g)		CH765	VRC41	Alam2017(28298421) 	Mutation affects neutralization of V3 mAbs	K	34		12.5647	7.41578	CH765-VRC41.02	
VRC42.01	gp41 MPER (membrane proximal external region)		40512		Krebs2019(30876875) 		K	0				RV217-VRC42.01	
VRC-CH30	gp120 CD4bs		CH0219	VRC-CH31	Wu2011(21835983) 		K	20		0.43176	18.5182	CH30	
VRC-CH31	gp120 CD4bs	4LSP(VRC-CH31 complexed with gp120 (93TH057));4LSQ(VRC-CH31 complexed with gp120 (93TH057/3514 chimera));4LSR(VRC-CH31 complexed with gp120 (93TH057/KER2008 chimera))	CH0219	VRC-CH31	Wu2011(21835983) 	Signature Analysis Summary;VRC-CH31 signature predictions	K	421		1.06961	16.5289	CH31, VRC-CH31 d0219	
VRC-CH32	gp120 CD4bs		CH0219	VRC-CH31	Wu2011(21835983) 		K	20		0.88113	19.1793	CH32	
VRC-CH33	gp120 CD4bs		CH0219	VRC-CH31	Wu2011(21835983) 		K	20		0.44584	16.2125	CH33	
VRC-CH34	gp120 CD4bs		CH0219	VRC-CH31	Wu2011(21835983) 		K	20		0.82068	15.5751	CH34	
VRC-PG04	gp120 CD4bs	7RSO(AMC016 SOSIP.v4.2 in complex with PGV04 Fab);7RSN(AMC018 SOSIP.v4.2 in complex with PGV04 Fab);3J5M(BG505 Env trimer with 3 PGV04 Fabs);6CRQ(Glutaraldehyde-treated BG505 SOSIP.664 in complex with PGV04 Fab);4I3S(gp120 complexed with VRC-PG04 space group P21);4I3R(gp120 complexed with VRC-PG04 space group P3221);EMD-7107(PC64M4c054 SOSIP in complex with PGV04 Fab);EMD-8302(SOSIP trimer from patient AMC011 in complex with Fab from IgG PGV04);3SE9(VRC-PG04 complexed with gp120)	Donor 74	VRC-PG04 	Wu2011(21835983) 	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary;VRC-PG04 alanine scanning;VRC-PG04 contacts;VRC-PG04 signature predictions	K	448	Yes	0.81585	15.4112	PG-04, PG04, PGV04, VRC04, VRC-PG-04, VRC-PG04 d74	
VRC-PG04b	gp120 CD4bs		Donor 74	VRC-PG04 	Wu2011(21835983) 	VRC-PG04b signature predictions	K	178		1.38148	22.7156	PG04b	
VRC-PG05	gp120 silent face	6BF4(HIV-1 Clade AE Strain CNE55 gp120 Core in Complex with VRC-PG05)	Donor 74		Zhou2018(29548671) 	Signature Analysis Summary;VRC-PG05 contacts;VRC-PG05 sensitivity and escape	K	272		22.7512	10.7914	PG-05, PG05, VRC-PG-05	
VRC-PG19	gp120 V2-CD4bs		IAVI 23		Zhou2013a(23911655) 	Mutations allowing binding of germline Abs	L	20		1.60753	16.0011	PG19, VRC-PG19 d23	
VRC-PG20	gp120 CD4bs	4LSU(VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120)	IAVI 23		Zhou2013a(23911655) 	Altered glycosylation affects neutralization by CD4BS bnAbs;Mutations allowing binding of germline Abs;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	L	183		0.69508	24.9562	VRC20, VRC-PG20 d23	
X5	gp120 CD4i	1RHH(Fab X5);2B4C(gp120 core protein containing V3 complexed with CD4 and the X5 antibody)	FDA2		Moulard2002(11997472) 		K	21	Yes			Fab X5	
Y498	gp120 CD4bs		XJ1981		Sun2017(28968970) 	Mutation decreases binding of Y498	K	70		50.8973	5.24214		
Z13	gp41 MPER (membrane proximal external region)		FDA2		Zwick2001b(11602729) 	Z13e1 contacts	K	0					
Z13e1	gp41 MPER (membrane proximal external region)	3FN0(Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41);3Q1S(Z13e1 in complex with epitope display protein)	FDA2		Nelson2007(17287272) 	Mutation affects Z13e1 binding;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary;Z13e1 contacts	K	125		76.4903	1.89348		
